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STUDIES ON GLP-1
ABSTRACT
In this project, different immunisation protocols were investigated in order to produce an immune 
response to truncated GLP-1 (7-36) in mice. GLP-1 (7-36) appears to be a poor immunogen. 
Mouse-mouse hybridoma cell lines were, however, obtained for GLP-1 (7-36) as well as N- and 
C-terminal fragments. These fragments have been synthesised using solid phase synthesis. The 
resulting peptides were pure as assessed by HPLC and FABMS.
Some of the monoclonal antibodies were specific for GLP-1 (7-36).
Attempts at producing polyclonal antisera gave low titre antibodies which failed to displace GLP-1 
(7-36) in a radioimmunoassay. Radiolabelling of GLP-1 (7-36) was studied and the Iodogen 
method was shown to be superior to the other method tried.
Studies, in vitro, with human and rat (RINm5F) insulinoma cells showed that GLP-1 (7-36) 
stimulated insulin release, the synthetic N- and C-terminal fragments also stimulated insulin release 
by human insulinoma cells.
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INTRODUCTION
1.1 GENERAL INTRODUCTION
The immunosystem is a large and complex series of elements widely distributed throughout the 
body. It has many functions, including protection against pathogens and reactions against foreign 
substances while not reacting against self components. The immunosystem as one of its primary 
abilities, accomplishes the distinction between self and non-self through an elaborate specific 
recognition system inherent in T and B lymphocytes. The immunosystem also contains non­
specific effector systems, which include the complement system and cells such as mononuclear 
phagocytes and polymorphonuclear leukocytes (PMN), which are often part of inflammatory 
responses.
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1.2 ELEMENTS OF THE IMMUNE SYSTEM
The immune system is a surveillance mechanism, that protects us from disease caused by 
microorganisms, such as bacteria and viruses, from parasites and from cancer. Immunology, the 
study of the immune system, has contributed significantly to modem medecine in areas such as 
blood transfusion, vaccination, organ transplantation, the treatment of allergy, autoimmune disease 
and cancer (Bailyes et al., 1987; Aguila et ah, 1986; M cClelland and  Yap, 1984; 
Grossm an, 1986; Edw ards, 1981 and W hite, 1985).
In vertebrates, immunity against microorganisms and their products is divided in two : innate or 
natural immunity and acquired immunity;
Innate (natural) immunity is present from birth and consists of many factors including internal and 
body surface components. These factors which include the skin, changes in the pH, secretion of 
fatty acids and the enzyme lysozyme operate against almost any substance that threatens the body. 
The internal elements involved in natural immunity are many, such as, substances released by 
leukocytes, some serum protein and the kinins. A number of cells e.g. granulocytes, macrophages, 
microglial cells and cytotrophoblasts are involved in the destruction and elimination of foreign 
material that has succeeded in penetrating the barriers of the immune system.
Acquired immunity is more specialised than innate immunity, it supplements the protection 
provided by innate immunity and is present only in vertebrates. Although an individual is bom 
with the capacity to mount the defences provided by acquired immunity, this form of immunity, to 
a foreign agent, is not exhibited unless that individual has had prior contact with the same agent 
(immunisation) which will trigger a chain of events that leads to the activation of lymphocytes and 
the synthesis of antibodies with specificity against the foreign agent. Unlike innate immunity,
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acquired immunity exhibits specificity. There are three major types of cells that participate in 
acquired immunity : B lymphocytes, T lymphocytes, and macrophages. There are two major 
components of acquired immunity : humoral immunity which is mediated by specific antibodies 
present in the serum and cellular immunity which is mediated by cells with the T lymphocytes 
being the antigen specific elements of cellular immunity, (Gamlin, 1988).
1.3 THE MAJOR LYMPHOID ORGANS AND TISSUES
The lymphatic organs are those in which maturation, differentiation, and proliferation of 
lymphocytes take place (Figure 1.1). There are two different lymphoid organs:
I) The primary or central lymphoid organs are those organs in which the maturation of T and 
B lymphocytes into antigen-recognizing lymphocytes takes place.
II) The secondary lymphoid organs are those organs in which antigen-committed lymphocytes 
are stimulated to undergo further division and differentiation.
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Figure 1.1. The lymphatic system; location of the principal components of the lymphatic 
system (Tortora and Anagnostakos, 1987).
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I) Primary or Central Lymphoid Organs
There are two major primary lymphoid organs, one in which the T-lymphocytes develop and the 
other in which the B-lymphocytes develop.
1) The Thymus Gland
The thymus gland (Figure 1.2) is a bilobed structure derived from the endoderm of the third and 
fourth pharyngeal pouches. The thymus is a lymphoepithelial organ and consists of lymphoid cells 
(thymocytes) and epithelial cells organised into cortical and medullary areas. T-lymphocytes mature 
in the cortex and migrate to the medulla which they then leave to enter the peripheral blood 
circulation through which they are transported to the secondary lymphoid organs. T-lymphocytes 
participate in cell-mediated immunity and in a variety of regulatory functions. Maturation of the T- 
lymphocyte involves the commitment of a given T-lymphocytes to recognise and respond to a 
given determinant or epitope of a foreign antigen. This recognition is achieved by a specific 
receptor on the T-lymphocytes. This commitment occurs only during fetal development and for a 
short time after birth. Only 5-10% of mature T-lymphocytes (also called thymocytes whilst still in 
the thymus) survive and eventually leave the thymus; 90-95% of all thymocytes die in the thymus 
(Benjamini and Leskowitz, 1988).
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2) Bursa of Fabricius or its Equivalent
The bursa of Fabricius is the primary lymphoid organ in birds, in which B-lymphocytes undergo 
maturation. It is situated near the cloaca and consists of lymphoid centers that contains epithelial 
cells and lymphocytes. The mammalian equivalent of this primary lymphoid organ, in which 
development and maturation of B-lymphocytes occurs, may be the bone marrow. Mature B- 
lymphocytes, each with antigen-specific receptors, are transported from the bursa, or equivalent 
structure, by the circulating blood to the secondary lymphoid organs where they encounter and 
respond to antigens (Weir, 1988).
II) Secondary Lymphoid Organs
The major secondary lymphoid organs are the spleen and the lymph nodes. They have two major 
functions:
A) They are highly effective in trapping and concentrating foreign substances.
B) They are the main sites of production of antibodies and generation of antigen-specific T- 
lymphocytes.
It is in these secondary lymphoid organs that the T-lymphocytes encounter and respond to foreign 
antigens and while T-lymphocytes do not themselves make antibodies, they help B-lymphocytes to 
do so by releasing lymphokines (soluble substances released by lymphocytes) e.g Interleukin-2 
(IL-2) (Benjamini and leskowitz, 1988).
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a) The Spleen
The spleen (Figure 1.3) is the largest of the secondary lymphoid organs. It is the major organ in 
the body in which antibodies are synthesised and from which they are released into the circulation. 
The parenchyma of the spleen consist of two different kinds of tissue called white pulp and red 
pulp. The white pulp is essentially lymphatic tissue, mostly lymphocytes are arranged around 
arteries called central arteries. In various areas the lymphocytes are thickened into lymphatic 
nodules referred to as splenic nodules. The red pulp consist of venous sinuses filled with blood 
and cords of splenic tissue called spleenic cords. Veins are closely associated with the red pulp. 
Splenic cords consist of erythrocytes, macrophages, lymphocytes, plasma cells and granulocytes. 
Approximately 50% of spleen cells are B-lymphocytes; 30-40% are T-lymphocytes (Tortora and 
A nagnostakos, 1987)
b) Lymph Nodes
The lymph nodes (Figure 1.4) are small ovoid structures, scattered throughout the body, usually 
in groups and range from 1 to 25 mm (0.04 to 1 inch) in length. These groups are arranged in two 
sets : superficial and deep. A lymph node contains a slight depression on one side called the hilus 
or hilum where blood vessels and efferent lymphatic vessels leave the node. Each node is covered 
by a capsule of dense connective tissue that extends into the node. The capsular extensions are 
called trabeculae. Internal to the capsule is a supporting network of reticular fibers and reticular 
cells (fibroblasts and macrophages). The trabeculae contain germinal centers, where lymphocytes 
are produced. The inner region of a lymph node is called the medulla. In the medulla the 
lymphocytes are arranged in strands called medullary cords. These cords also contain macrophages 
and plasma cells (Benjamini and Leskowitz, 1988).
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The circulation of lymph through a node involves afferent lymphatic vessels (which convey 
towards the centre), sinuses and efferent lymphatic vessels (which convey away from the centre). 
The afferent lymphatic vessels enter the convex surface of the node at several points. They contain 
valves that open towards the node so that the lymph is directed inward. Once inside the node, the 
lymph enters the sinuses which are a series of irregular channels. Lymph from the afferent 
lymphatic vessels enters the cortical sinuses just inside the capsule. Then it circulates to the 
medullary sinuses between the medullary cords. After that the lymph usually circulates into one or 
two efferent lymphatic vessels. The efferent vessel is located at the hilus of the lymph node. It 
contains valves that open away from the node to convey the lymph out of the node. Lymph passing 
from tissue spaces through lymphatics on its way back to the cardiovascular system is filtered 
through lymph nodes which remove foreign substances. The macrophages destroy the foreign 
substances by phagocytosis, T-lymphocytes may destroy them by releasing various products, and / 
or B-lymphocytes may produce antibodies that destroy them (Tortora and Anagnostakos,
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1.4 IMMUNE RESPONSES
Entry of antigen into the body triggers an amazing defensive system. The antigen is trapped by 
accessory cells (macrophages) and its antigenic determinants are presented efficiently to B- and T- 
lymphocytes. Antigen stimulated B- and T-lymphocytes interact specifically with one another to 
trigger proliferation and differentiation into effector cells. These terminally differentiated cells and 
their products combine with the antigen and initiate several overlapping mechanisms for its 
elimination (Hood et al., 1984).
1.4.1 Regulation of the immune response
The immune response is complex and may exert deleterious effects on the body. Its evolution was 
accompanied by the development of highly sophisticated and very precise mechanisms for the 
regulation of the nature and extent of the response. Disturbances in these regulatory mechanisms 
may be caused by conditions such as a congenital defect, infection or hormonal imbalance any of 
which may have disastrous consequences.
The acquired immune deficiency syndrome (AIDS) is a defect in the regulation of the immune 
response and the subject of much current research. As a result of infection with the human HIV 
virus, there is a decrease in one sub population of T-lymphocytes (the helper T-lymphocytes) that 
leads to an immunological deficiency which render the patient susceptible to infectious 
microorganisms, that are normally benign, and to malignancies, the most common of which is 
Kaposi’s Sarcoma (Chapel and Haeney, 1988).
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1.4.2 The cellular basis of the immune response
The major characteristics of the cellular basis of the immune response are as follows:
1) Specificity: This is the ability to discriminate between different antigenic epitopes and to
respond only to those that necessitate a response rather than to make a random 
undifferentiated response.
2) Memory : This is the ability to recall previous contact with a particular antigen.
3) Affinity maturation and changes in classes of immunoglobulins: As the immune 
response proceeds, the affinity of antibody for antigen tends to increase and additional 
class of immunoglobulin tend to be produced.
4) Adaptiveness : This is the ability to respond to previously unseen antigens.
5) Discrimination between self and non self: this is the ability to respond to those antigens
that are not self but to avoid making responses to those antigens which are part of self.
The clonal selection theory proposed and developed by Burnet (1959). This theory explains the 
general features of an immune response:
1) Antibodies of all specificities are produced prior to contact with antigen.
2) B-lymphocytes have antigen recognition receptors on their surface membranes.
3) Each lymphocyte carries immunoglobulin molecules of only a single specificity on its
surface.
1 4
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4) The circulating self antigens that reach the developing lymphoid system prior to its 
maturation are recognised as self and no subsequent immune response will be induced 
against them.
5) Immunocompetent lymphocytes which are not shut off or deleted in this process can be
stimulated under appropriate conditions by antigen to proliferate and differentiate into 
clones of antibody producing plasma cells and memory cells.
1.4.3 The genetic control of the immune response
The search for genes that control the capacity of an animal to make a particular immune response 
has continued for decades. Given the complexity of the steps involved in such a response, it is 
obvious that regulatory mechanisms can operate at several levels. It has been recognised that 
successful blood transfusion is dependent on matching the blood groups of donor and recipient red 
cells. Similar considerations are involved in the acceptance or rejection of other transplanted 
tissues. Histocompatibility antigens (HLA), the term was coined for the antigens involved in graft 
rejection. The products of one particular region of the genome were of predominent importance in 
the rejection process. This region is the major histocompatibility complex (MHC) referred to as H- 
2 in the mouse and located on chromosome 17. In man, the MHC is the human leukocyte antigens 
(HLA) gene cluster on chromosome 6 and one HLA haploid genotype (haplo type) is derived from 
each parent. The MHC was originally identified by its role in transplant rejection, it is now 
recognised that proteins encoded in this region are involved in many aspects of immunological 
recognition including interaction between different lymphoid cells as well as between lymphocytes 
and antigen presenting cells (Festenstein and Demant, 1978).
15
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1.5 ANTIBODY STRUCTURE
One of the major functions of the immune system is the production of soluble proteins that circulate 
freely and exhibit a variety of properties. These soluble proteins are antibodies called 
Immunoglobulins (Igs). Immunoglobulins incorporate several features which are essential for their 
participation in the immune response. The two most important of these features are specificity and 
biological activity.
1.5.1 Antibody specificity and cross-reactivity
Cross-reactivity of antibodies has been one of the most serious problems immunologist have faced 
over the years. Specificity requires a mechanism that limits the molecules with which the antibody 
can combine to those that contain one particular antigenic structure. The existence of a vast array of 
potential antigenic determinants has necessitated the evolution of a system for producing a 
repertoire of molecules, each of which is capable of combining with a single antigenic structure. 
Thus, antibodies exhibit not only great diversity in terms of the types of molecular structure with 
which they are capable of reacting but also a high degree of specificity since each is able to react 
with only one antigenic determinant. An immunologic reactions in which the immune components, 
either cells or antibodies, react with two molecules that share antigenic determinants but that are 
otherwise dissimilar is called a cross-reaction. When two compounds cross-react immunologically 
it means that the compounds have one or more antigenic determinants in common and that the 
immune response to one of the compounds recognises one or more of the same antigenic 
deteminant(s) on the other compound and reacts with it. Another form of cross-reactivity is seen 
when antibodies to one determinant bind, usually more weakly, to another determinant that is not 
quite identical but has structural resemblances to the first determinant. In cases of cross-reactivity 
the antigenic determinants of the cross-reacting substances may have identical chemical structures
1 6
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or they may be composed of similar but not identical physicochemical configurations. The common 
antigenic determinant that are found on unrelated substances are referred to as heterophile antigens.
1.5.2 Antibody biological properties
One part of the antibody molecule is adapted to allow tremendous variation in the determinants that 
can be recognised (Fab). The other part must be adapted to allow the antibody to participate in the 
biological functions that are common to all antibodies (Fc). Many important biological properties 
are attributable to antibodies. These properties include neutralisation, immobilisation, agglutination 
and the ability to cross the placenta from the mother to the foetus. Not all antibody isotypes are 
equal in the performance of all of these biological roles. The differences in the various biological 
activities of the antibodies are attributable to their isotypic (class) structure. Although all antibody 
isotypes that are induced by immunisation can be directed against a given antigenic determinant or 
epitope, the differences between the isotypes account for the different consequences of binding 
with antigen. The antibody molecule has two major roles : to bind with antigen and to participate in 
one or more of the biological functions cited above. These two roles are performed by two 
different parts of the molecule, the first by the Fab and the second by the Fc. The determination of 
the structure of antibody and the establishment of the relationship between the structure, function 
and the elucidation of the genetic organisation of the (Ig) molecule has led to an understanding of 
the evolution of a sophisticated highly specialised system in which diverse structures 
(immunoglobulins) all recognise the same antigen, but in which combination of immunoglobulin 
with antigen leads to an array of diverse biological effects (Hilschmann et al., 1978).
Figure 1.5 is an illustration of immunoglobulin G (IgG) structure. Two identical heavy chains (H) 
and two identical light chains (L) are joined in a Y-shape by covalent disulphide bridges between 
the two heavy and between the two light chains units which constitute the main linkage forming the 
whole antibody molecule. The two arms have the same structure and they are the parts of the
17
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molecule that combine with the antigen (Porter, 1967). In the N-terminal half of the polypeptide, 
the sequences were found to vary greatly from one light chain to another. In the C-terminal half of 
the polypeptide, the sequences of all the molecules were identical (Capra et al., 1975 b).
The variable region of the heavy and light chains (Vjj  and V]J consist of approximately 110 amino 
acids residues. The heavy chain constant (Qh ) region at the carboxyl C-terminal of the IgG
molecule is approximately 330 residues long. There are five immunoglobulin classes which are 
distinguished structurally by differences in their heavy chain constant region (Cjj)- The Cjj  region
amino acid sequences show that there are five major heavy chain classes, designated a , y, 8, 8 and 
p. These heavy chain classes define the corresponding immunoglobulin classes : IgA, IgG, IgD, 
IgE and IgM respectively (Fig. 1.6). There are two major types of light chains, K and X, based on 
comparisons of the constant region amino acid sequences. The immunoglobulin classes exhibit 
different physiochemical properties from each other (Table 1.1).
18
INTRODUCTION
C arbohydra te
cha in
A ntigen-
b ind in g
siteI
Fab un it Fab un it
A n tig e n -
b i n d i n g
site
Figure 1.5 . Schematic drawing of the three-dimen ional structure of an IgG molecule. Each 
amino acid residue is represented by a small sphere. One of the H chains is 
shown in dark red, the other in dark blue. One of the L chains is shown in light 
red, the other in light blue. A carbohydrate unit attached to a Cyp- domain is
shown in yellow (S tryer, 1988).
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CLASS BASIC STRUCTURE PRINCIPAL FUNCTIONS
IgG
IgM
IgA
IgD
IgE
protects extravascular 
compartment from 
microorganisms 
and their toxins
effective first line 
of defense against 
microorganisms in 
the bloodstream
protects mucosal 
surfaces
may influence 
lymphocyte functions
protects against 
intestinal parasites, 
responsible for many 
of the symptoms 
of allergy
Figure 1.6 . Immunoglobulin classes. IgG illustrates the basic structure of the immunoglobulin 
molecule which consists of two identical heavy and two identical light polypeptide 
chains. IgM is a pentamer of this basic structure, IgA is a dimer, IgD differs 
relatively little, while IgE possess an extra globular domain. The different functions 
served by these classes are listed.
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Table 1.1
IgGI
lgG2
lgG3
tgG4
IgM
!gAi
igA2
slgA
IgD
IgE
. The physicochemical properties of human immunoglobulin subclasses.
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1.6 MONOCLONAL ANTIBODIES
Monoclonal antibody is the name given to an antibody produced by a single clone of cells. 
Monoclonal antibody is the product of immortal cell line which is like a myeloma but has the 
genetic elements of antibody producing cells. These immortal cells are achieved by cell fusion 
(Figure 1.7). Myelomas are the malignant proliferation of immunoglobulin producing cells. The 
production of experimental plasmacytomas demonstrated that it is possible not only to transplant 
afixed number of cells but also to adapt them to continuous culture and to grow them in vitro 
(H oribata and H arris, 1970). A myeloma cell line was fused with spleen cells from an 
immunised mouse donor to produce a murine hybridoma (Kohler and Milstein, 1975). The 
first fusion of mice spleen cells which had been immunised with sheep red blood cells with mouse 
myeloma cells illustrated the potentiality of this technique. The time for fusion is three to four days 
after the final immunisation of the mouse. The polyethylene glycol (PEG) was introduced as a 
fusion promoter. PEG was first applied in fusion of mammalian somatic cells by Pontecorvo 
(Pontecorvo, 1975) and has since been described as universal fusogen (Power et al., 1978 
and Lucy, 1978) because of its action on a wide range of cells.
The development of monoclonal antibodies of purely human origin has been hampered by lack of 
available myeloma fusion partners which will support the secretion of immunoglobulin. The 
plasmacytomas represent the most differentiated of lymphoid malignancies and seem to be one of 
the most difficult human malignant cells to establish in continuous culture. Recently, Epstein-Barr 
virus (EBV) has been used to facilitate the production of human monoclonal antibodies (James 
and Bill, 1987). Tan et. al, (1987) have used mouse myeloma cells (NS1 cell line) in the 
production of human monoclonal antibodies. A more modem method using a heteromyeloma as a 
fusion partner has been used (Moyle et al., 1988).
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Figure 1.7 . Monoclonal antibodies production.
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1.6.1 H ybridom as
The formation of monoclonal antibodies can be conveniently separated into three phases. The first 
phase is the cellular fusion, the second is the selection phase and the third phase is antibody 
production.
PHASE ONE : The cellular fusion phase
There are three requirements for this phase (Wester W oudt et al., 1983 and 1984)
1) Suitable antigen for immunisation.
2) Cells that can be immunised.
3) A mutant myeloma culture for fusion.
A common method for producing monoclonal antibodies uses an immunised mouse as the source 
of the cells and a murine myeloma cell line, deficient in hypoxanthine guanine phosphoribosyl 
transferase (HGPRT), as the mutant myeloma line. Hybridoma cells are valuable because they 
potentially have the best attributes of both parents, the genetic information to produce an antibody 
from the spleen cells, the cellular machinery to enable production and indefinite life in tissue culture 
from the myeloma cells.
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1.6.2 The mechanism of cell-cell fusion and the fusogenic ag en ts
Cell-to-cell fusion plays a decisive role in many biological processes and in vitro cell-to-cell fusion 
is of great important for membrane research, genetic mapping, and somatic hybridisation. 
Traditionally, cell-to-cell fusion has been achieved, in vitro, by chemical agent the most common 
being polyethylene glycol (PEG) (Pontecorvo, 1975 and 1976) and inactivated sendi virus 
(Yelton et al., 1981).
There are three stages involved in the mechanism of cell-cell fusion mediated by viruses and 
chemicals, (Knutton and Pasternak, 1979).
1) Agglutination
2) Membrane fusion between adjacent cells.
3) Osmotic swelling of the fused cells.
Polyethylene glycol (M.W. 600-6000) is now the preferred fusion agent giving a high fusion 
frequency with little effect on viability. The main function of the hydrophilic PEG is to occupy the 
physical free water space leading to agglutination of the cells. This occurs at concentrations of PEG 
in the region of 40-50% and most of the fusions are performed within this range (Harlow and 
L a n e ,1988)
Electrofusion, avoids the use of chemicals or viruses and prevents structural changes thereby 
permitting cell fusion to be induced in a controlled manners. It has been used to produce fusion 
between different cell types includes plant and yeast protoplasts and also between mammalian cells 
and liposomes. Electrofusion can now be used in studies requiring cell-cell hybrids, thereby
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increasing hybrid yield and eliminating the deleterious effects of fusogenic agents on cell 
populations (Kohler et al., 1976 and Zimmermann et al., 1981).
1.6.3 H ybrid cell partners
Unless there are specific reasons against it, the myeloma should be of the same species as the 
immunised animal. This will permit easy development of tumours when hybrid myelomas have 
been derived. Antibody secreting hybrids are derived from antigen stimulated B-lymphocytes and a 
myeloma cell line (Kohler and M ilstein, 1976). The primary source of stimulated B- 
lymphocytes has usually been the secondary lymphoid organ (the spleen). The choice of a rat or a 
mouse as an immunised animal is based on several consideration. The most important is the 
relative immune response to the antigen. If, after immunisation of different rats and mice, 
individual animals show a better response, the myeloma parent cells should be chosen to match that 
animal.
A considerable number of permanent cell lines exist (Potter, 1972). The tumour cell lines used 
most frequently in hybridoma production are listed in Table 1.2.
The most important consideration is the immunoglobulin chain secretion of the myeloma. 
Hybridomas codominantly express the immunoglobulin chain of both parent cells.
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Table 1.2 . Myeloma cell lines used as fusion partners
Derived Chains
Cell line from expressed Secreting
Mouse lines
P3-X63Ag8 P3K Yl.K IgGl
X63Ag8.653 P3-X63Ag8 None No
Sp2/0-Agl4 P3-X63Ag8xB ALB/c None No
FO Sp2/0-Agl4 None No
NSVl-Ag4-l P3-X63Ag8 Kappa No
NSO/1 NSVl-Ag4-l None No
FOX-NY NSI/l-Ag4-l Kappa No
Rat lines
Y3-Agl.2.3 Y3 Kappa No
YB2/0 YB2/3HL None No
IR983F LOU/c rats None No
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PHASE TWO : Hybridisation and selection
A great many detailed protocols are available for the production of monoclonal antibody secreting 
hybrids (Oi and H erzenberg, 1980 and Galfre and M ilstein, 1981). For a successful 
hybridisation two essential features are necessary. Firstly, the availability of rapidly dividing 
antigen- stimulated, antibody-producing cells. This is dependent on the success of the 
immunisation regime (e.g. specific efficiency) employed with the spleen cell donor (Anderson 
and M elchers, 1978).
Secondly, the status of the myeloma cells prior to fusion. The efficiency of fusion is greatest when 
the myeloma cells are maintained in the logarithmic growth phase for an extensive period before 
fusion. Consequently when 90% or more of the myeloma cells are viable then can be used to make 
fusions.
After fusion the most important requirement is the use of a selection medium to allow recovery of 
hybrids from the fusion mixture. The fusion mixture will contain the desirable myeloma-spleen 
hybrids as well as myeloma-myeloma hybrids and spleen-spleen hybrids, in addition to unfused 
myeloma and spleen cells. The unfused spleen cells and the spleen-spleen hybrids are terminally 
differentiated and therefore die after a very short time in culture. The unfused myeloma cells and 
the myeloma-myeloma hybrids will persist indefinitely under the optimum growth conditions. 
However, a selection technique is used which eliminates all these unwanted cells from the fusion.
DNA can be synthesised by two pathways : the salvage pathway and the denovo pathway. The 
enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT) is used in the salvage 
pathway to produce the nucleotides inosine-5-phosphoribosyl (IMP) and guanosine-5- 
phosphoribosyl (GMP) (Figure 1.8). The hybrid cells can be selected over either parental cell by
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culturing in a medium containing hypoxanthine, aminopterin and thymidine (HAT medium) 
(Figure 1.9) . The myeloma cells, which lack HGPRT (an enzyme from the DNA salvage 
pathway), can not survive because the denovo DNA synthesis pathway is blocked by the folate 
antagonist aminopterin. The hybrid cells, in which a functional HGPRT gene is supplied by the 
lymphocyte genoma, grow rapidly and form large colonies. Clones of hybrid cells that produce a 
desired antibody can be identified by a suitable assay procedure and grown into larger cultures.
1.6.4 Screening of hybridom as
In the last few years most workers in monoclonal hybridoma production have agreed that the 
success or failure of specific monoclonal hybridoma production (high specific efficiency) depends, 
to a large extent, on the screening methods. The screening method must be rapid-because desirable 
hybrids have to be identified quickly-and very sensitive to give a strong positive result. The 
method that is used should be able to deal with hundreds of samples in a matter of hours with a 
good deal of sensitivity (M iller et al., 1983; Vaidya et al., 1985 and  K enna et 
al.,1985). It is very important to select the screening method with the subsequent application of 
the antibodies in mind. Antibodies are frequently detected by their binding to the specific antigen 
followed by detection with a fluorescent, or an enzyme-labelled second antibody to specific 
immunoglobulin.
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Purines
  HGPRT
salvage: Hypoxanthine------- ^  Inosinic acid ribose phosphate
(6-oxypurine)
HGPRT
Guanine  ► Guanine acid-ribose phosphate
(6-aminopurine)
Adenyisuccinic acid 
de novo: ^
small molecules — ► Inosine •  DNA
monophosphate Adenosine   ^  RNA
monophosphate
Xanthosine 
monophosphate
Guanosine
g lutam ine__________ ^  monophosphate
Pyrimidines
TK
salvage: D eoxythym id ine Thymidine monophosphate
\
DNA 
RNA
de novo: deoxyuridine monophosphate
t
small molecules   ^  deoxycytidine monophosphate
•Figure 1.8 . Nucleic acid biosynthesis - The basic biochemical pathways for the biosynthesis 
of purines and pyrimidines are shown. The pathways available to the cell include 
the de novo and salvage routes.
HGPRT = hypoxanthine guanine phosphoribosyl-transferase 
TK = thymidine Kinase
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Blocked by Aminopterinde novo
GMP
TMP
HGPRT
GMPguanine
hypoxanthine
TK
»  TMPdeoxythymidine
Figure 1.9 . Biochemical basis of the use of HAT supplemented medium - There are two 
biosynthetic routes to DNA and RNA, the de novo and the salvage pathways. 
Aminopterin, a folic antagonist blocks the de novo pathway and hence only the 
salvage pathway may be utilised. If the cell possesses the raw materials (thymidine 
and hypoxanthine) and the enzymes required it will be capable of nucleic acid 
synthesis. The mouse myeloma line NSI lacks the HGPRT and thus is unable to 
make DNA by either pathway in HAT supplemented medium and therefore dies.
HAT = hypoxanthine aminopterin thymidine
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PHASE TH R EE : Antibody production
1.6.5 C loning
The positive clones of hybrid cells can be expanded into larger vessels and/or stored in liquid 
nitrogen as a reference stock if problems occurs during the cloning procedure. The timing of the 
cloning requires careful consideration. It is best to attempt to grow clones as soon as possible after 
screening and finding positive clones because some antibody clones are slow growing and, in 
some cases, unstable due to chromosome segregation. Cloning may be carried out in soft agar 
(Hudson and Hay, 1983) which facilitates positive clone selection directly. Alternatively, the 
cultures may be cloned by limiting dilution (Hudson and Hay, 1983). The cells are diluted so 
that they may be grown in small number per well.
A fluorescence activated cell sorter employes a fluorescent antigen which marks the specific 
antibody-producing cells and allows simultaneous selection and cloning. In these circumstances the 
growth in the wells follows the Poisson distribution (Lefkovits and W aldm ann, 1979). On 
this premise, single clone cultures may be selected visually and positive cultures grown for further 
investigation. Further cloning may be carried out to ensure monoclonality.
1.6.6 Feeder
Normal spleen cells, thymocytes or peritoneal macrophages can be used as feeder cells (Levy et 
al., 1978; Ham m erling et al., 1978 and Kennett et al., 1978) in fusion protocols to 
increase the yield of viable hybrids after the fusion step. They are essential for isolating hybrid 
clones, that are otherwise difficult to grow. Feeder cells improve cloning efficiency, which is 
usually low, especially in newly isolated hybrids (Hudson and Hay, 1983). The use of feeders
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cells should be limited so that the hybrids will not become feeder dependent. Feeder cells can be 
used to reduce possible toxic effects of plastic culture vessels (Goding, 1980) and macrophage 
feeder cells have phagocytic activity which may assist in keeping contamination in check.
17 POLYCLONAL ANTIBODIES
Knowledge of some immunological principles may help the investigator before he proceeds with 
the preparation of antibody. The ability of an animal to elicit an immune response depends upon the 
properties of the immunogen as well as complex interaction between it and the physiological state 
of the specific animal of choice. It is known that not all proteins or polypeptides elicit an immune 
response under a standard set of conditions and that the method by which the antigen is presented 
can influence the response. There are major differences in response to the same macromolecule 
from species to species and among strains within a specific species (Borek, 1972). 
Nevertheless, it is known that by employing the correct ,carrier, and conjugation procedure for 
normally non-immunogen compounds an immuno response can be elicited to almost any large or 
small molecules. The molecular weight and complexity in structure of the macromolecule 
influences the nature of the immune response. In general, the greater the molecular weight and the 
more complex the protein or polypeptide structure, the greater the response that can be expected. 
There are three main factors that influence the immune response:
I) Animal species
The most common animals used for immunisation are mice, rats, rabbits, guinea pigs, chickens, 
goats, sheep, donkeys, and horses (W eir, 1978). Important consideration in choosing the 
species are the source and availability of immunogen. Ordinarily, one cannot obtain large amounts 
of serum from repeated bleedings of mice, rats or even guinea pigs. Whereas larger amounts can 
be obtained from goats, sheep, donkeys and horses.
3 3
INTRODUCTION
II) Genetic factors
Many of the ’genetic1 factors that govern immune responses to simple and complex synthetic 
polymers as well as to proteins, have been reviewed by McDevit and Landy, (1973). Immune 
responses by inbred strains of guinea pigs, mice and rats to many immunogens are controlled by 
immune response genes present in the major histocompatibility complex (HMC) of the respective 
species (Benacerraf, 1975).
HI) Properties of the antigens
There is a good relationship between a protein's immunogenicity and its physiochemical properties 
and these can indictate the outcome of the immune response. The state of aggregation of a protein 
has long been recognised as a factor involved in its immunogenic potential (Pinckuck and 
M urer, 1965).
Many studies reached the conclusion that protein antigens may contain two general classes of 
determinant structures namely, sequential and conformational. Sequential determinants would be 
those occuring in a linear conformation, as in the unfolded of a protein. Conformational 
determinants would be those that are recognised by the homologous antibodies only when they 
occur in a particular conformation. The latter class include determinants formed from amino acids 
that are located at distant points in the peptide chain but come into proximity with each other when 
a particular conformation is achieved (Arnon and Sela, 1969). It also seems likely that proteins 
displaying quaternary structure have unique determinants that can be considered 'conformational' 
(Reichlin, 1975). It is generally accepted that a relationship exists between the structural 
complexity of a compound i.e the variety of its components, and its ability to induce an immune 
response (B-Efrain et al., 1967). In general, there is a direct relationship between an antigen's 
molecular size and its capacity to stimulate an immune response (Becker et al., 1973).
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1.7.1 Im m unisation
One should use techniques that might enhance the immune response especially when dealing with 
valuable or expensive protein or polypeptide . Although responses can be obtained against either 
solutions of soluble antigens or suspensions of particulate antigens, still better responses can be 
elicited by use of 'adjuvants'. An adjuvant allows the use of much less immunogen. It increases 
the persistence of antigen in the host and can protect the antigen from degradation by the usual 
proteolytic enzymes. Adjuvants allow concentration of the antigen into a particulate carrier so that 
the amount of antigen administered per unit volume is increased.
The commonly used adjuvants are remarkable for their diversities. The most popular and 
successful adjuvants have been the water in oil emulsions. The basic ingredients are light mineral 
oil e.g. Bayol and emulsifying agent mixtures such as Arlacel (A or C). The reagents are 
emulsified with either solutions or suspensions of the immunogens incomplete Freund’s adjuvant. 
The addition of mycobacteria e.g. mycobacterium butyricum, mycobacterium tuberculosis in small 
amounts to the suspension (complete Freund's adjuvant) leads to a further enhancement of the 
immune response. This has been attributed to the increased local inflammatory response caused by 
the mycobacteria (White, 1963).
The stable emulsuion is injected either intraperitonealy, intradermally, intravenously or into 
footpads of the host. If complete Freund's adjuvant has been used for the first injection, the 
secondary injection should not contain the mycobacteria, as a further immune response against the 
mycobacteria can be detrimental to the host and also lead to enhanced inflammatory responses. A 
final consideration in regard to antigen dosage is that of the amounts used for immunisation affects 
the affinity and specificity of the antibodies that are produced.
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1.7.2 Antibody production
For immunisation of large animals such as rabbits, sheep or goats, small to moderate amounts of 
the antigen should be used (0.1-1.0mg/kg of body weight). A boost injection can be given after the 
prime injection. This is most likely to be effective if given after the antibody level has dropped. It is 
important to have appropriate intervals between injections and to be careful not to reinject antigen 
if high levels of antibody are still present in the circulation. When the antibody level is rising 
slowly, or has decreased, it is beneficial to reinject the animals with incomplete Freund's adjuvant 
in addition to the antigen. Pooling of sera from different animals is not recommended, as reactions 
to different determinants might have occured in different animals. In addition, if the immunising 
preparation is not absolutely pure, it is conceivable that some animals might have responded to the 
impurities. Antibodies specific for antigenic determinants (idiotopes) expressed by the variable 
domains of other antibodies (termed A bl) are known as anti-idiotypic (or Ab2). Some anti- 
idiotypic antibodies, specific for a given Abl, are able to mimic properties of the antigen (or its 
determinants) also bound by Abl. Anti-idiotypic mimicry has been observed for a wide variety of 
molecule e.g. insulin (Sege and Peterson, 1978). Changes do occur in the properties of the 
antibody produced over a period of time. In general, high affinity antibody follows immunisation 
with low doses of antigen and the best sera can be obtained in rabbits about 3-5 months after first 
immunisation. Although not always predictible, animals that respond early after immunisation 
usually produce the best antibody (Siskind and Benacerraf, 1969).
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1.8 PEPTIDES AND PROTEINS
It is veiy remarkable that proteins from all forms of life-plant, animal or microbial contain only the 
same 20 amino acids. Each amino acid has a distinctive side chain which provides its chemical 
individuality. Living cells can join the amino acids in many different combinations and sequences 
yielding peptides or proteins with different properties and activities. Most amino acids have one 
asymmetric carbon atom, is a carbon to which are bound four different substituent groups, the 
exceptions are glycine, which has no asymmetric carbon atom and threonine and isoleucine which 
have two asymmetric carbons. Proteins or peptides can be hydrolysed by heat, strong acid or base. 
Hydrolysis is necessary to determine the amino acid sequence of proteins or peptides.
Fifty percent or more of the solid dry matter of living cells consist of proteins. Proteins are found 
in all cells and in all parts of cells. The molecular weight of proteins has been investigated by 
physical methods such as osmotic pressure measurements or by depression of freezing point 
(cryoscopic) determinations. Proteins are of two shapes; globular proteins and fibrous proteins. 
The protein structures are stabilised by two classes of weak bonds (hydrogen and hydrophobic). 
The primary structure of protein is the order of individual amino acids in the polypeptide chain. 
The secondary and tertiary structures of proteins are the conformations of polypeptide chains.
1.8.1 Chemical synthesis of proteins
Chemical synthesis of polypeptides and proteins in vitro is a difficult undertaking because of the 
following points:
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1) Successful protein synthesis demands ordered sequential coupling of amino acids with little
by-product formation. This is achieved by the use of protecting groups for amino carboxyl 
functions and potentially reactive amino acid side chains.
2) The protecting groups must be both easily attached to the reactants and removed from the
products under mild conditions and in high yield.
3) The growing peptide chain is kept convalently attached to an entirely insoluble support
throughout all stages of the synthesis.
4) One hundred percent qauntitative incorporation of each amino acid residue must be 
accomplished.
5) Peptide synthesis should be fast and convenient.
6) Homogeneity, purity and solubility problems.
1.8.2 Peptide synthesis
Synthetic peptides, and in particular those with biological activity, have become of great interest to 
investigators in many branches of science and medicine. One of the most important advantages of 
peptide synthesis is a knowledge of the chemical composition of the compound. A number of 
peptide such as oxytocin and ACTH have been synthesised. Solid-phase peptide synthesis offers 
many advantages over conventional solution phase synthesis, in particular simplicity of operation 
and dramatic savings of time. The Merifield method appear to provide the ideal means for 
peptide and protein synthesis. Solid-phase peptide synthesis attracted wide attention and has been
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found to have numerous applications not only by peptide chemist but by biochemists, biologists, 
pharmacologists, physiologists, endocrinologists and immunologists.
1.8.3 Solid phase peptide synthesis
In 1963, Merifield demonstrated that peptide bond formation could be achieved efficiently when 
one of the N-protected amino acids was condensed with an amino acid or peptide bond via the 
carboxyl group to an insoluble polymeric support (Figure 1.10). This has proved to be one of the 
most important developments in the history of the peptide synthesis. The unique feature of solid 
phase peptide synthesis is the solid support itself.
The general requirements for solid phase are as follows:
1) It should contain reactive sites to which the peptide chain can be attached and later removed.
2) It must be stable to the physical and chemical conditions of the synthesis.
3) It should allow rapid, unhindered contact between the growing peptide chain and the 
reagents.
4) It should be readily separable from the liquid phase at every stage of the synthesis and be 
physically stable during synthesis.
5) The support must provide enough points of attachment to give a useful yield of peptide per 
unit volume.
6) The support should minimise the interactions between bound peptide chains.
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There are two recomended solid supports to be considered (Bodanszky, 1988), the polystyrene 
and the poly-dimethylacrylamide solid supports. The organic solvent used is dichloromethane for 
the polystyrene, and dimethylformamide (DMF) for the polydimethylacrylamide, based solid phase 
synthesis. The synthesis initiated by ester bond formation between the first N-protected amino acid 
and the resin bond linkage agent using symmetrical anhydride activation in the presence of 
dimethylaminopyridine as a catalyst. Subsequent residues are added, usually as N-protected amino 
acid symmetrical anhydrides, without a catalyst but with intermediate cleavage of protecting groups 
(Figure 1.10).
There are three common types of linkage agents:
1) Acid labile linkage agent (ALLA).
2) Highly acid labile linkage agent (HALLA).
3) Base labile linkage agent (BLLA).
N,N-dichlorohexylcarbodiimide (DCCI) is an acid labile linkage agent and the most widely used 
linkage agent in solid phase peptide synthesis. It is used to couple the amino acids and the 
reference amino acid to the solid phase. The reference amino acid can be any amino acid. It is 
recommended to have a reference amino acid added to the resin to check that the resin is activated 
and to help the peptide clevage (Personal communication). Active esters, such as P-nitrophenyl 
esters and pentafluorophenyl esters of a variety of amino acids have been successfully used in solid 
phase synthesis. The coupling of two amino acids can be done by two methods:
I) The amino group of the amino acid can be activated then reacted with the carboxyl group 
of the second amino acid.
II) the two amino acid can react together (one amino protected, the other carboxyl 
protected) in the presence of a coupling agent.
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For the formation of peptide bonds the carbodiimide method was introduced by Sheenhan and 
Hess (1955). The success of the carbodiimide method was because of its high reactivity even in 
the presence of water. In addition, the ready commercial availability of dicyclohexyl carbodiimide 
was certainly an important factor. Using N,N-dicyclohexyl carbodiimide (DCCI) in the coupling 
method is very simple, and the fact that there is very little tendency to racemisation offers a major 
advantage over conventional solution phase synthesis (Andreade et al., 1953).
Active esters have been used successfuly in solid phase peptide synthesis because it is possible to 
accelerate peptide bond formation by using an ester that cleaves easily. Aminolysis of the activated 
ester will provide the energy necessary for peptide bond formation.
Protection and deprotection are important steps in peptide synthesis. Three essential conditions 
must be met during deprotection:
1) Quantitative removal of the Na-protecting group.
2) Complete stability of the peptide to polymer bond.
3) Complete stability of certain side chain protecting groups and in particular those of the 
co-amino functions.
There are three groups to be protected in the peptide synthesis :
I) a-Am ino group
*
The a-amino group can be protected by alkylation or by sulphonylation (Fisher, 1915). There 
are different varieties of acyl protecting groups for the amino function. The fluorenyl 
methoxycarbonyl function (Fmoc) group which can be removed by secondary amines, typically
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piperidine (Atherton et al., 1978). The use of (Fmoc) amino acids permit synthesis under very 
mild reaction conditions and raises the yield of peptide (Atherton and Sheppard, 1977).
II) Carboxyl group
The protection of the carboxyl group of an amino acid is accomplished by esterification. The 
methyl or ethyl ester may be synthesised by reaction of the amino acid with gaseous hydrochloric 
acid (HCL) in methanol or ethanol. The ester function can be removed under mild conditions. The 
use of benzylalkyl esters such as t-butyl allows removal of the protecting group under neutral 
conditions and after the peptide has been cleaved from the resin (Young et al., 1967).
III) Side chain group
The side chain functional groups of tri-functional amino acids e.g. Lysine, Arginine, Methionine 
... etc, must be protected during synthesis procedures. The protecting groups used for this purpose 
must be stable to all reagents used for removal of an a-amino or carboxyl group during synthesis. 
No loss of side chain protection must occur during deprotection of the active amino acids. The 
combination of protection based on the benzyl group (e.g. benzyl ester, benzyloxycarbonyl group) 
with that based on tertiary alkyl groups (e.g tert-butyl ester, tert-butyloxy carbonyl group) has 
proven to be extremely valuable in the peptide synthesis (Schroder and Lubke, 1966).
The finished peptides can be removed from the resin support by either nucleophilic displacement of 
the peptide by hydrogen bromide in an anhydrous tri-fluoro acetic acid or using a scavenger in 
TFA such as ethanedithiol or methionine upto 5% (v/v) (Losse, 1973).
The chemical difficulties encountered in solid phase synthesis of peptide can be classified as 
follows:
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1) Difficulty in bringing to completion individual coupling reactions. The Kaiser test is a colour 
test for detection of residual unreacted amine groups. Use of this test permits the detection of 
incomplete deprotection steps which would otherwise go largely unnoticed until the end of a 
synthesis.
2) Catastrophic failures associated with sudden cessation or major reduction of amino acid 
incorporation.
3) Side-reactions caused by chemical sensitivity, protected peptides sequences, individual 
peptides chains and the harshness of the reaction conditions employed.
1.9 THE ENDOCRINE SYSTEM
The endocrine system consists of a number of internal glands or groups of secreting cells with a 
wide variety of activities, many of which are interrelated. The role of the endocrine glands is to 
act, with the nervous system, as the means whereby the functions of the body are controlled. Many 
hormones are polypeptides ranging in chain length from three to nearly two hundred amino acids. 
Many of the polypeptide hormones are known to be synthesised from a 'prohormone'.
The protein and polypeptide hormones are probably stored exclusively in secretory granules within 
the cytoplasm of their respective endocrine cells. However, it is possible that some hormone is 
always present 'free' in the cytoplasm, but unless it is protected in some way from inactivation by 
proteolytic enzymes, this component is unlikely to be stable. Storage of the hormone within the 
granules is probably the principal way in which the hormone is protected from intracellular 
degradation, but another way could be by association of the hormone with another molecule or 
element (e.g. insulin with zinc), the complex formed then possibly existing within the cytoplasm.
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1.9.1 Preproglucagon gene expression
Pancreatic proglucagon m-RNA has been cloned and sequenced from different species using 
recombinant DNA techniques (Bell et al., 1983(a&b); Lopez et al., 1983 and Heinrich 
et al., 1984a). Proglucagon has been shown to be the precursor of glucagon (Patzett and 
Schiltz, 1984). Proglucagon is made up of 180 amino acids containing five functional regions ;a 
signal or pre-peptide, an amino-terminal peptide (also called glicentin-related pancreatic peptide, 
GRPP) glucagon, and two carboxy-terminal glucagon-like peptides, GLP-I and GLP-II), (Figure 
1.11). Glicentin has 69 amino acids and contains the entire glucagon sequence at positions 33-61. 
Glucagon and each of the two glucagon-like peptides is flanked by pairs of basic amino acids that 
are characteristic of the sites that are cleaved during the post-transitional processing of 
prohormones resulting in the liberation of specific bioactive peptides (Steiner et al., 1980).
1.9.2 Glugagon and glucagon-like im m unoreactivity peptides
Glucagon is a 29-amino acids pancreatic hormone which counter acts the blood glucose lowering 
action of insulin by simulating hepatic glucogenolysis and gluconeogenesis (Bell et al., 1983 
b). The kidneys are the major site of glucagon catabolism. Different molecular forms of glucagon 
or glucagon-like immunoreactivity (GLI) are present in the circulation. In uraemia an abnormally 
large fraction of the total glucagon-like immunoreactivity in plasma has been reported to have a 
molecular size corresponding to 8000-9000 dalton (Jaspan et al., 1981). The total of GLI have 
been found in the circulation of uraemic pigs by simple gel filtration of plasma. The glucagon- 
related peptides bears the immunodeterminants for the glicentin sequence 1-61. The most 
remarkable difference is the complete absence of glicentin 15-80 immunoreactivity, showing that 
this sequence is not found in the human enteroglucagon molecules. Nevertheless the majority of 
the glucagon-like immunoreactivity, as determined with the glucagon 6-15 assay was found in a
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peak with the same Kd and therefore probably the same size of glicentin (Holst et al., 1987). 
This means that in human intestinal mucosa there must be an analogous 'human glicentin' which 
however, differs in the N-terminal sequence from its porcine counterpart The C-terminal sequence 
of the 'human glicentin' could very well be similar to the C-terminal sequence of porcine glicentin.
1.9.3 Glugagon like peptides I & II
Glucagon like peptides I and II sequences are shown in (Figure 1.12). The amino acid sequence of 
GLP-I is completely conserved between human (Bell et al., 1983 b), ox (Lopez et al., 
1983), guinea pig (Holst et al., 1987), rat (Heinrich et al., 1984 b), hamster (Bell et 
al., 1983 a), (Figure 1.13) and that may have certain significent biological roles. Glucagon-like 
peptide-I and glucagon have 14 amino acids in identical positions (Figure 1.12). However, the 
gene and mRNA nucleotide sequences do not provide information about the post-translational 
processing of the peptide precursors and it therefore remained unresolved whether or not glucagon­
like peptides are actually formed. Evidence that these glucagon-like peptides are proteolytically 
processed from the pro-hormone in several tissues has accumulated (Thim and Moody, 1981). 
Detection of both GLP-I (1-37) and GLP-I (7-36) in the isolated perfused rat pancreas and 
intestines raises the possibility that GLP-I (1-37) is itself a prohormone that undergoes a 
proteoly tic clevage at the single arginine residue at position 6 to release the biologically active GLP-
I (7-37), (Mojsov et al., 1987). Kreymann et. al., (1987) have measured GLP-I in the 
was
plasma when ittinfused into human volunteers.
The amino acid sequence homology of GLP-II between human and hamster is 92.2% and between 
human and bovine it is 85% (Hoosein and Gurd, 1984).
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Proglucagon residues Trivial name Structural representation
(1-159) Proglucagon YY f • Y T - f c o c H
(1-69) Glicentin
(enteroglucagon)
|— ' ii - n
(1-30) GRPP I I
(33-69) Oxyntomodulin i----------in
(33-61) Glucagon 1 i
(72-108) GLP-1
l l ._ ...
(78-108) GLP-1(7-37) 
(insulinotropin)
1 Z D
(126-158) GLP-2
Figure 1.11. A schematic representation of human preproglucagon and the principle product of 
post-translational processing of preproglucagon (Conlon, 1988) .
4 7
INTRODUCTION
1 2  3 4 5 6 7 8 9 10 11 72 13
GLP-I His- Asp- Glu- Phe- Glu- Arg- His- Ala- Glu- Gly- Thr- Phe- Thr-
GLP-II His- Ala- Asp- Gly- Ser- Phe- Ser- Asp- Gly- Met- Asp- Thr- Iie-
Glucagon His- Ser- Gln- Gly- Thr- Phe- Thr-
7 2 3 4 5 6 7
74 75 16 77 18 19 20 21 22 23 24 25 26
GLP-I Ser- Asp- Val- Ser- Ser- Tyr- Leu- Glu- Gly- Gin- - Ala- Ala- Lys-
GLP-II Leu- Asp- Leu- Ala- Ala- Arg- Asp- Phe- Iie- Asp- Trp- Leu- Iie-
Glucagon Ser- Asp- Tyr- Ser- Lys- Tyr- Leu- Asp- Ser- Arg- Arg- Ala- Gln-
8 9 10 77 72 13 14 75 16 77 75 19 20
27 28 29 30 31 32 33 34 35 36 37
GLP-I Glu- Phe- Iie- Ala- Trp- Leu- Val- Lys- Gly- Arg- Gly
GLP-II Gln- Thr- Lys- Iie- Thr- Asp- Arg
Glucagon Asp- Phe- Val- Gln- Trp- Leu- Met- Asp- Thr
27 22 23 24 25 26 27 28 29
Figure 1.12 . The amino acid sequences of GLP-I, GLP-II and pancreatic glucagon. (Bell et
al. 1983, and Holst et al. 1987)
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Species Residue no. in hum an proglucagon
72 78
Human His- Asp- Glu- Phe- Glu- Arg- His- Ala- Glu- Gly- Thr- Phe- Thr-
Gx ? > >» i » >» >» j> »» »» *) »» »» >» »»
Guinea Pig » >) »» >» »» »> »» j > s» >» »» »»
R ^ - t  5 5  5 5  5 5  )  )  ) )  » >  J )  » J  ) )  » J  J  » J  > > 5
Hamster ,, ,, ,, ,, ,, ,, ,, ,, ,, , ,  ,, ,,
Species Residue no. in hum an proglucagon
Human Ser- Asp- Val- Ser- Ser- Tyr- Leu- Glu- Gly- Gin- Ala- Ala- Lys-
G x  , ,  5 5  5 5  5 ,  ) )  5 )  ) )  ) J  ) J  ) )  ) )  ) )  !  >
Guinea Pig 55
R a t  55  55 55 55 55 5 5  5 5  55 5 5  5 5  5 5  5 5  5 5
Hamster 99 99 99 99 99 99 99 99 99 99 99 99 9 9
Species Residue no. in hum an proglucagon
107 110
Human Glu- Phe- lie- Ala- Trp- Leu- Val- Lys- Gly- Arg- Gly- Arg- Arg
G x  55  55  5 5  5 ,  5 ,  5 5  5 5  55  5 5  5 5  5 5  55  5 5
Guinea Pig 55 55 55 55 55 55 55 55 55 55 55 55 5 >
Rut 5 5  5 5  5 5  55  55  5 5  5 5  55  5 5  5 5  5 5  5 5  5 )
Hamster 99  9 9  9 9  9 9  99  9 9  9 9  99  9 9  9 9  9 9  99  9 9
Figure 1.13 . Sequences from 5 species of proglucagon regions containing glucagon-like 
peptide-1. Glucagon-like peptide-1 containing sequences of proglucagon from all 
species whose proglucagon structure has been determined. The peptide which 
was originally designated GLP-1 (of Hamster proglucagon) corresponds to 
proglucagon 72-108. („) Same amino acid as in human proglucagon. Vertical 
line between amino acids 77 and 78 indicates position of N-terminal amino acid 
in glucagon-like peptide-1 (Holst et al., 1987).
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1.9.4 The physiological role of glucagon-like peptides
The glucagon-like peptides sequences were designated glucagon-like peptides I and II (GLP-I and 
GLP-II) because of the remarkable sequence homology with members of the glucagon secretin 
family; glucagon in particular. Thus, GLP-I and glucagon have 14 amino acids and GLP-II and 
glucagon have 11 amino acids in identical positions (0rskov et al., 1986). The high degree of 
sequence conservation of GLP-I and GLP-II has suggested that these peptides have important 
physiological functions (Lopez et al., 1984). GLP-I and GLP-II were each found to be potent 
stimulators of both rat hypothalamic and pituitary adenylate cyclase but, they do not activate 
adenylate cyclase in rat liver plasma membranes and this suggests that glucagon-like peptides may 
be neurotransmitters and/or neuroendocrine effectors, which would account for their high degree 
of sequence conservation through vertebrate evolution (Hoosein and G urd, 1984). Schmidt, 
et al., (1985) investigated the insulin releasing activity of chemically synthesised GLP-I and 
GLP-D in collagenase isolated rat pancreatic islets kept in short term tissue culture. They found that 
GLP-I augments glucose induced insulin release, whereas GLP-II does not show this activity. 
Ghiglione et al., (1985) have shown that GLP-I does not bind to receptors on rat liver 
membranes nor displace glucagon from the glucagon receptors. They also showed that in isolated 
rat hepatocytes,GLP-I would not stimulate the production of cyclic AMP. Hepatic carbohydrate 
metabolism is not effected by GLP-I.
D rucker et al., (1987) have shown that rat insulinoma cells, in the presence of GLP-I, had 
increased c-AMP levels. GLP-I may therefore be a physiologicaly modulator of insulin gene 
expression. The GLP-I (7-37) potently increased insulin secretion from the perfused pig pancreas 
(Holst et al., 1987). Mojsov et al., (1987) showed that GLP-I (7-37) but not GLP-I (1- 
37)was a potent stimulator of insulin secretion in the isolated perfused rats pancreas. The entro- 
insular axis of ob/ob mice was uneffected by GLP-I(l-37) (Bailey and Flatt, 1987). Specific
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binding of GLP-I (7-36) to rat insulinoma derived RINm5F cells was time and
temperature dependent and proportional to cell concentration (Goke and Conlon, 1988).
Recently, Majsov and Habiner, (1988), showed that GLP-1 (7-36) was a more potent incretin 
than gastric inhibitory polypeptide. Unger and Eisentraut (1969) proposed the term entero- 
insular axis to describe a regulatory system in which the endocrine secretion of the pancreatic islets 
was modified to some extent by the gastrointestinal hormones. Gastric inhibitory polypeptide, 
gastrin, cholecystokinin, secretin, vasoactive intestinal polypeptide and glicentin are the incretin 
candidates. The incretin candidates stimulate insulin secretion in the presence of glucose if 
exogenously infused in amounts not exceeding blood levels. The dependency of the incretin effect 
upon the glucose level, at least, in physiological concentrations of the hormone is an important 
prerequisite of this principle for prevention of hypoglycaemia. Thus an incretin can be released by 
different intestinal contents, but elevated incretin blood levels stimulate insulin secretion only in the 
presence of elevated blood glucose levels, i.e. when insulin is needed.
Proproglucagon was processed in the brain in the same manner as in the intestine and not as in the 
pancreas (Yoshimoto et. al., 1989). Cleaving a single arginine residue, producing GLP-I(7- 
36)was shown in rat (Mojsov et al., 1986) and pig (Holst et al., 1987). This phenomena 
has not been shown in human.
The insulin release by human insulinoma cells was enhanced by GLP-I (1-37), GLP-I (7-36) and 
its N- and C-terminal fragments GLP-I (7-14) and GLP-I (31-37). GLP-I(7-14) enhanced the 
insulin release by rat insulinoma derived RINm5F cells (Flatt et al., 1989).
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1.10 GENERAL AIMS OF THE PRESENT WORK
Glucagon Like Peptide-1 (7-36) may play an important role in insulin release. Several publications 
in the 1980s helped in understanding the physiological role of GLP-1. Immunoassays have not yet 
been developed for wider use to measure GLP-1 (7-36) in serum. However, if some workers 
managed to develop a radioimmunoassay to measure GLP-1 (7-36) in the extracted tissue, the 
antibodies are rather limited from the viewpoint of quantity and quality. A better assay could be 
developed, standarised and put into a wider use.
I therefore undertook to synthesise the N- and C-terminal fragments of GLP-1 (7-36) and raise 
both monoclonal and polyclonal antibodies to the biosynthetic human GLP-1 (7-36) and its 
terminal fragments. The produced antibodies would be used in the development of an 
immunoassay to measure the whole GLP-1 (1-37) and the insulinotropic GLP-1 (7-36) in the 
plasma. A major part of the project was dedicated towards the development of these antibodies. 
Attempts were made to identify the effect of different immunisation protocols on the production of 
monoclonal antibodies and the effect of on the iodination of GLP-1 (7-36) and GLP-1 (1-37). 
A study of effects of GLP-1 (7-36), GLP-1 (1-37), N- and C- terminal fragments on human 
insulinoma cells and rat insulinoma RINm5F cells would also help in the investigation of the 
physiological role of glucagon-related peptides. A computer graphic art modelling of GLP-1 (7-36) 
and its terminal fragment was carried out by Dr. D. Lewis from the department of Biochemistry .
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2.1 GENERAL INTRODUCTION
Proteins are the most abundant macromolecules in living cells and constitute 50% or more of their 
diy weight. They are found in all parts of cells. Proteins are the most abundant source of antigenic 
substances. Litle is known about the molecular structure of antigenic determinants (epitopes) on 
protein molecules or about the way in which a specific antibody molecule can recognise one out of 
a virtually infinite array of protein epitopes. It is very remarkable that proteins from all forms of 
life, plant, animal or microbial contain the same 20 amino acids. The solid phase technique is the 
major technique to produce useful peptides where they can be used as' antigens to produce 
antibodies.
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2.2 MATERIALS AND METHODS
2.2.1 Materials
1) 2g of insoluble resin (Poly-dimethylacrylamide resin) were used to synthesise the peptides. The 
solid phase support was supplied by Dr. M. Munns, Chemistry Department, Surrey University.
2) All the activated and protected amino acids were purchased from Milligen Cambridge Research
Biochemicals (CRB), (Tables 2.1 and 2.2).
3) The acid labile linkage agents (ALLA), N-N-dicyclohexycarbodiimide (DCCI), 1-hydroxy- 
benzotriazole Ester (HOBT), N-N'-dimethylaminopyridine (DMAP), the scavengers 1,2- 
ethanediathiol and thioanisole were obtained from Aldrich, U.K.
4) The dimethylformamide (DMF), dichloromethane (CH2CI2), diethylether (Et2 0 ), kaiser test 
reagents, the HPLC grade organic solvents were obtained from BDH Chemicals, Ltd, U .K .
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Table 2.1 The N-terminal fragment of GLP-I(7-36)-NH2 peptide synthesis.
The sequence : His - Ala - Glu - Gly - Thr - Phe - Thr - Ser.
Formula weight = 846.00
Amino Acid Weight / mg mmol
Fmoc-Ser (tBu) 612.80 1.60
Fmoc-Thr (tBu) 450.00 0.80
Fmoc-Phe 442.00 0.80
Fmoc-Thr (tBu) 450.00 0.80
Fmoc-Gly 370.00 0.80
Fmoc-Glu (otBu) 472.00 0.80
Fmoc-Ala 381.00 0.80
Fmoc-His 514.00 0.80
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Table 2.2 The C-terminal fragment of GLP-I(7-36)-NH2 peptide synthesis.
The sequence : Trp - Leu - Val - Lys - Gly - Arg - Gly. 
Formula Weight = 814.00
Amino Acid Weight / mg mmol
Fmoc-Gly 475.20 1.60
Fmoc-Arg (Mtr) 486.00 0.80
Fmoc-Gly 370.00 0.80
Fmoc-Lys (Boc) 507.00 0.80
Fmoc-Val 404.00 0.80
Fmoc-Leu 415.00 0.80
Fmoc-Trp 473.00 0.80
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2.2.2 M ethods
Figure 1.10 (chapter 1) illustrates the peptide synthesis procedures.
1) Resin : The resin was treated with diaminoethane overnight in a sealed flask with gentle 
agitation. The resin was transferred into a large sintered glass funnel and washed with DMF 
several times and twice with 20% triethylamine in DMF.
2) Reference Amino Acid : The reference amino acid used for the peptide synthesis was Fmoc- 
Arginine.
3) Linkage Agent : Acid labile linkage agent (ALLA), N-N-dicyclomethexylcarbodiimide 
(DCCI) was used.
4) Kaiser Test : Kaiser test is a test to check the completeness of the amino acid coupling 
reaction.
K aiser Reagents
A) 1 gram of ninhydrin dissolved in 20 ml of ethanol.
B) 80 gram of phenol dissolved in 20 ml of ethanol.
C) 2 ml of 0.001M potassium cyanide (KCN) solution diluted to 100 ml with pyridine.
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K aiser assay
A sample of the resin was taken and placed in a small glass tube, 3 drops of each reagent (A, B 
and C) was added, then heated at 100°c for 5 minutes. A colour change occurs from colourless 
to either yellow/orange (a negative result) or blue/violet (a positive result).
5) Instrum en t : The instrument used for solid phase peptide synthesis was a simple pump 
connected to a column packed with 2 grams of solid phase. The pump had scale from (10-100). 
The pump, equipped with two valves and tubing connections which allowed manual sample 
application, deprotection, and washing as shown in Figure 2.1. Appropriate reagents are drawn 
through to the reaction vessels (column) via rotary valve. The other rotary valve allows reagents 
either to flow to waste or to be recycled through a reaction vessel in order to extend the reaction 
time.
6) The Synthesis Cycle for each Amino Acid :
I) The column was washed with the DMF for 10 minutes.
II) Deprotection of the N-protected amino acid with 20% pipyridine in DMF is permitted for 10
minutes.
III) Another wash with DMFis carried out for 10 minutes to permit equilibration of the solid 
phase.
IV) The appropriate amino acid in the chain is added and left to recyle for 2 hours.
V) Wash with DMF for 10 minutes to get rid of all the remaining unreacted reagents.
VI) Testing completion of the coupling by the kaiser test, which should be negative at this 
stage, and positive after deprotection, i.e the amino acids were coupled one to the other on 
stepwise synthesis.
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Figure 2.1 . The machine used for solid phase synthesis.
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7) A ttachm ent of the first amino acid to the linkage agent: A symmetrical anhydride 
formation method was used to attach the first amino acid. The solid phase was equilibrated 
initially with N-N-dimethyl aminopyridine (as a catalyst). The appropriate quantity of Fmoc- 
Ser and Fmoc-Gly were dissolved in 2-3 ml of dichloromethane in a small conical flask 
separately. 164.80 mg (0.80 mmol) of N-N-dicyclo carbodiimide (DCCI) was dissolved in 
dichloromethane and added to the amino acid solution (2 molar equivalents Fmoc-AA + 1 
molar equivalent DCCI were used).
The reaction mixtures was left for 10-15 minutes at room temperature. The precipitated 
dicyclohexyl urea was filtered off through a pasteur pippete with a glass wool plug. The 
dichloromethane was evaporated by using a rotary evaporator, the residue was dissolved in 2-3 
ml DMF and filtered again through a glass wool plug. This solution was pumped into the resin 
by turning the pumping rate down to about 10 on the pump scale. The solution was pumped 
into the solid phase in the column and left to recycle for 30-40 minutes after the pumping rate 
was raised up to about 40 on the pump scale. The excess of unreacted reagent were washed 
away by DMF. The kaiser test was carried out on a small amount of the solid phase, the result 
was negative. The amino protected group was deprotected with 20% pipyridine in DMF. The 
solid phase was equilibrated with DMF, after which the kaiser test was positive.
8) Coupling the second amino acid to the resin : The second protected amino acid was 
Arginine Fmoc-Arg(Mtr)-OH in the C-terminal of GLP-I. A hydroxybenzotriazole (HoBt) ester 
formation method was used to couple the Fmoc-Arg(Mtr)-OH. An appropriate quantity of 
Fmoc-Arg(Mtr)-OH was dissolved in dichloromethane, and a solution of HoBt in DMF was 
added to the amino acid, followed by solution of DCCI (1 molar equivalent Fmoc-AA + 1 
molar equivalent DCCI + 1 molar equivalent HoBt were used). The reaction mixture was left 
for 10-15 minutes at room temperature, and was stirred occasionally. The dicyclohexyl urea
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(DCU) was filtered off through a pasteur pipette glass wool plug. The dichloromethane was 
evaporated, the residue was dissolved in 2-3 ml DMF and filtered again as before. The solution 
was pumped into the resin and left to recycle for 2 hours. The kaiser test was negative before 
the deprotection and positive after the deprotection.
9) Coupling the rem ainder of amino acid to the resin : All the amino acids used were 
pentafluorophenyl (-opfp) activated esters except Threonine (Thr) Fmoc-Thr(But)-oDhbt, 
which was the dihydroxybutyl ester (-oDhbt). An activated ester method was used to couple 
the remaining amino acids. The appropriate quantity of the active ester was dissolved with the 
appropriate quantity of the HoBt in 2-3 ml DMF (1 molar equivalent Fmoc-AA-opfp + 1 molar 
equivalent Hobt were used).The solution was filtered through a small plug of glass wool in a 
pasteur pipette as before. The solution was pumped into the column and left to recycle at room 
temperature. The resin was washed with DMF, and the amino protected groups were 
deprotected and the resin was equilibrated with DMF as before.
10) Cleavage from the resin : After completing the synthesis the peptide is cleaved from the 
resin. The resins, with peptides attached, were removed from the glass reaction columns and 
placed in scintered glass funnels (Figure 2.2). The resins were washed five times with 
dichloromethane and three times with diethylether and then left to dry in air. The resins in the 
funnels were treated with 95% (v/v) trifluoroacetic acid (TFA) containing 5% (v/v) scavengers 
(Thioanisole 2.5% (v/v) + ethanedithiol 2.5% (v/v)) for 1 hour. This was repeated three times, 
and the TFA solutions were collected. Treatment with TFA and scavenger was repeated and left 
overnight. The resin was then drained and washed with neat TFA. The TFA was evaporated to 
a very low volume (approximately 0.5ml) using a rotary evaporator then washed with 
diethylether several times. The excess of diethylether was pipetted off, leaving a clean white 
precipitate containing the peptide.
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Rubber teat 
(to stop the solution 
draining into the 
flask during reaction 
time)
Round-bottom
flask
Figure 2.2 . The peptides cleavage from the resin.
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11) C h ro m ato g rap h y  : The analysis of the peptides was performed on Water's Liquid 
Chromatography (HPLC). The analytical column was a C18 reverse-phase column 25x0.5 cm 
octadecasilyl (ODS) partisil 5 fim operated at room temperature and 1 ml/minute flow rate. The 
solvent were made up with filtered double glass distilled water.
Solution A : 0.1% (v/v) TFA in water,
Solution B: 0.1% (v/v) TFA in acetonitrile.
The gradient was built up from a starting solvent of 5% B to 95% B over 20 minutes. Peaks 
were detected at 230 nm using model variable wavelength UV detector (Figure2.3). Two 
major peaks were detected with slight impurity.
12) Fast Atom Bom bardm ent Spectrom etry (FAB MS): The low field spectrum of 
samples were run from M12 1000 down wards,for the N-terminal (M.W. 846) and the C- 
terminal (M.W. 814). The strongest signal was observed over the M12, 847 downwards for 
the N-terminal and 815 downwards for the C-terminal. Fast atom bombardment (FAB) 
analysis was carried out on an analytical ZAB-SE. High field magnet spectrometer operating 
VACC 8KV for 846 and 814 mass ranges at full sensitivity. Xenon gas was used to generate 
spectra. Samples of both synthetic peptides were loaded onto a target to obtain their molecular 
ions. The two peptides, (N and C terminal peptides) gave strong signals at m/z 847 and 815 
respectively.
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C-terminal fragment N-terminal fragment
Figure 2.3 . The high performance liquid chromatogram of synthesised N- and C-terminal 
fragments.
HPLC gradient system 
Cjg reverse-phase column
The gradient system
5% B 95% B
Solvent A: 0.1% TFA in distilled water 
Solvent B: 0.1% TFA in acetonitrile 
Time of run: 20 minutes 
Row rate: 4 ml/min 
Charter speed: 200 mm/hr 
Wavelength: 230 nm
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2.3 DISCUSSION
A symmetrical anhydride as a coupling method for the first amino acid is always recommended. 
The hydroxybenzotriazole (HoBt) ester formation coupling method was used in the case of 
arginine because it has different (OH) protecting group. The advantages of using the 
hydroxybenzotriazole ester and dicyclocarbodiimide in the coupling method were the complete 
elimination for the formation of the undesired acyl urea derivatives and the lowest level of 
recimisation. The HPLC and FAB MS results indicated slightly impure peptides and correct 
molecular weight for each terminal fragment peptide. The N- and C-terminal fragments of GLP-I 
(7-36) were successfully synthesised. No physical characterisations were carried out on the 
synthetic peptides.
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3.1 GENERAL INTRODUCTION
Monoclonal antibodies are produced by hybridoma cell lines. Each antibody forming cell and its 
clones are capable of secreting identical antibodies. This hybrid is created by fusing a myeloma cell 
and the antibody forming cell. There are large number of fusion protocols in general circulation and 
these have produced a large number of viable antibodies. These variations sometimes are minor 
variations such as the molecular weight of the PEG used and the fusion incubation time 
(Davidson et al., 1976, G efter et al., 1977, Pontecorvo et al., 1977, Fazekas de 
st Groth and Scheidegger, 1980 and Klebe and M ancusa, 1981). The hybridoma cells 
can be stored and retrieved to obtain the same antibody whenever needed.
Injection of hybrid cells into mice or rats will result in tumour formation after 2-4 weeks. 
Intraperitoneal injection is the preferred route, because it will often result in the development of 
ascites in some individuals. The antibody levels in ascites are not greatly different to those in 
serum, and range from 5-15 mg/ml (Goding, 1986). The success rate in tumour development, 
and the probability of ascites formation, are increased by injecting 0.5 ml pristane or incomplete 
Freund’s adjuvant (Goding, 1986 and Harlow and Lane 1988).
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3.2 MATERIALS AND METHODS
3.2.1 M aintenance and investigation of NSI myeloma cells
The myeloma cell line P3-NSI/l-Ag4-l was used throughout the project. NSI myeloma cells were 
maintained routinely in tissue flasks in the standard culture media containing 10% fetal calf serum 
at a densities of between 2 - 4x10^ cells/ml. The cells usually divided every three days and fresh 
media was then added. The flasks were usually placed in a humid 5% CO2 in air environment at
37°c. The day before the fusion the cells were harvested and resuspended in fresh media. The NSI 
growth and viability curves were obtained by incubating 1x10^ myeloma cells in 10 ml of standard 
media. Trypan blue dye (Difco laboratories, U.K.) 5g/l in 0.01M phosphate buffered saline (PBS), 
pH 7.4 was placed in a tube containing NSI cells in order to distinguish dead from live cells. A 
haemocytometer was used to count the number of viable cells which was between 90-95% on the 
fusion day.
3.2.2 Peptides conjugations
A. G lucagon-Like peptide-l(7-36) - egg album in / keyhole lim pet hem ocyanin  
conjugations
Glucagon-like peptide-1(7-36) (Peninsula laboratories, inc. U.S.A) (M.W. 3297.50) was 
conjugated to egg albumin (M.W. 45000). The molar ratio of egg albumin to glucagon-like 
peptide-1(7-36) used was 1:4 previously shown to result in antibody production (Shibier et al., 
1988). lmg GLP-l(7-36) was dissolved in 3 ml sterile water. 3.4 mg egg albumin was dissolved 
in 5 ml sterile water. 0.4ml 25% gluteraldehyde was added to the peptide solution then this was 
added to the egg albumin solution. The mixture was then placed in a dialysis sac and dialysed 
against water 2-3 days.
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Glucagon-like peptide-1(7-36) was also conjugated to keyhole limpet hemocyanin (M.W. 
3000000-7500000). The molar ratio of keyhole limpet hemocyanin to glucagon-like-1(7-36) used 
was 1:600 (Shibier et al., 1988). lmg GLP-1(7-36) was conjugated to 1.52mg keyhole limpet 
hemocyanin, as per egg albumin conjugate.
B. N-terminal fragment-egg albumin / keyhole limpet hemocyanin conjugations
The N-terminal fragment (M.W. 846) was conjugated to egg albumin. 5mg N-terminal fragment 
was dissolved in 13 ml sterile water was conjugated to 66.5 mg egg albumin dissolved in 20 ml 
sterile water (molar ratio of 1:4, egg albumin to peptide) using 2 ml 2.5% gluteraldehyde, as per 
section 3.2.2,A . Vials each contain 100 jig of the dialysised mixture were ffeezed dried before 
use.
The peptide was conjugated to keyhole limpet hemocyanin. The molar ratio was 1:600, keyhole 
limpet hemocyanin to peptide. 5mg N-terminal peptide was conjugated to 29.5 mg keyhole limpet 
hemocyanin using gluteraldehyde condensation method, as per section 3.2.2,A.
C. C-terminal fragment-egg albumin / keyhole limpet hemocyanin conjugations
The C-terminal fragment (M.W. 814) was conjugated to egg albumin. 5mg C-terminal fragment 
was dissolved in 13 ml sterile water was conjugated to 69 mg egg albumin dissolved in 20ml sterile 
water (molar ratio 1:4, egg albumin to peptide) using 2 ml 2.5% gluteraldehyde, as per section 
3.2.2^A . The vials each contain 100 jig of the dialysised mixture were ffeezed dried before use.
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The peptide was conjugated to keyhole limpet hemocyanin. The molar ratio was 1:600, keyhole 
limpet hemocyanin to peptide. 5mg C-terminal peptide was conjugated to 30.5mg keyhole limpet 
hemocyanin using gluteraldehyde condensation method, as per section 3.2.2,A .
3.2.3 Immunisation
Females Balb/c mice at 8 weeks old (Banton and Kingman, U.K.) were immunised as indicated in 
Table 3.1 . The peptide-egg albumin conjugates were used for immunisation. The resulting 
conjugate was mixed with equal volume of Non-Ulcerative Freund's Adjuvent (NUFA) to give a 
final concentration of 50 fig/ml. The solution was mixed vigorously until a stable emulsion 
formed. The emulsions were injected into the mice. Just before killing the mice to obtain the 
spleen for fusion. The mice were bled andthe antisera screened.
3.2.4 Screening
Indirect enzyme liked immunosorbent assay (ELISA) was used to screen the monoclonal antibodies 
(Figure 3.1).
A. GLP-l(7-36) monoclonal antibodies
The soft plates (Dynatech laboratories, U.K.) were coated with GLP-l(7-36)-keyhole limpet 
haemocyanin conjugate at a concentration of lfig/lml diluted in 0.1 M bicarbonate carbonate buffer, 
pH 9.6 (200 }il/well). The plates were incubated overnight at 4°c in a moist box. Next day the 
plates were washed 4 times with 0.15M phosphate buffer saline, pH 7.4 containing 0.1% gelatine 
and 0.05% tween 20 (PBSGT) all further washing and diluting were carried out using this buffer.
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The hybridoma supematants/sera were added to the assay wells (200fil /  well) in duplicate and the 
plates were then incubated for 2 hours at 37°c in a moist chamber. The wells were then washed as 
before. Peroxidase-labelled donkey anti-mouse serum was added to the plates (200pl /  well) for 2 
hours at 37 °c. The plates were washed again and (150|il /  well) substrate solution (orthophenyle- 
nediamine) was added to all wells. The plates were then incubated at 37°c for 30 minutes in a moist 
box. The reaction was then stopped by adding 50jil of 2.5M sulphuric acid and the wells read on 
automated ELISA reader (Flow labs., U.K.) at a wavelength of 490 nm.
B. N-term inal fragm ent monoclonal antibodies
The assay protocol as in section 3.2.4,A except, the ELISA plates were coated with l|ig/ml N- 
terminal fragment-keyhole limpet haemocyanin conjugate.
C. C-term inal fragmentM onoclonal antibodies
The assay protocol as in section 3.2.4,A except, the ELISA plates were coated with 1 |ig/ml C- 
terminal fragment-keyhole limpet haemocyanin conjugate.
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Table 3.1. Immunisation schedules and their effects on the frequency of specific hybridomas.
Antigen GLP-1 (7*36) N-terminal fragment C-terminal fragment
Immunization Method A B A B D A c D
Number of mice 2 3 2 3 1 2 2 1
Immnnmtirti
1. mice aged 8-10 weeks Lp. 10*ig io m ityg i(Vg 10ug io m io m 10pg
2. mice aged 12-14 weeks Lp. 10pg io m io m io m 10m io m 10m io m
3. mice aged 16-18 weeks Lp. 10m io m 10m 10m 10m 10m 10m io m
Final immunisation (mice aged 20-22 weeks)
4. day 4 Lp. io m io m 10m io m ' 100m io m 100m 100m
3. day 3 Lp. o m io m o m io m 200m Om ioom 200m
6. day 2 Lp. Om io m o m io m 200m o m 100m 200m
7. day 1 Lp. o m 10m Om io m 200m o m 100m 200m
8. day 0 Fusion Fusion Fusion Fusion Fusion Fusion Fusion Fusion
— Lp.t intenperitooeally
— AD quantities refer to the amount of peptide were injected.
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Step  1 
coat the plate with 
G L P -l(7 -36)  
conjugate
wash in PBSGT
S tep  2 
add the hybridomss 
supernatants/mouse 
antiserum
wash in PBSGT
Step 3 
add donkey anti-mouse 
lgG  peroxidase 
label to  all wells
wash in PBSGT
Step 4
JL\°0
Figure 3.1 . The indirect enzyme linked immunosorbent assay (ELISA)
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3.2.5 Spleen cells
The spleen was dissected from the mouse and transferred to a sterile plastic petri-dish containing 
10ml serum free media. The spleen was pressed against sterile stainless steel mesh. The clumps of 
cells were further dispersed by pipetting up and down with a sterile plastic pipette. The cells were 
then collected into a sterile centrifuge tube. The cells were counted using a haemocytometer.
3.2.6 Fusion and plating out
The NSI and the spleen cells (ratio 1:5, NSI: spleen cells) were mixed in a large 50 ml centrifuge 
tube. After centrifugation the pellet was washed in 10 ml serum free media. The pellet was 
loosened by tapping the container and to this was slowly added 0.8ml of 50% w/v polyethyelene 
glycol 1500, stirring continuously. 10 ml serum free media was then added over a period of 5 
minutes. The fusion media contained lxHAT (aminopterin, hypoxanthine and thymidine) 
(selection media). The cells were plated in 24 wells culture multidish and incubated in a humid 5% 
CC>2 in air environment at 37°c.
3.2.7 Cloning
As soon as positive wells were identified by ELISA screening method, the cells were expanded 
into a larger culture plates and then cloned by limiting dilution. The hybridomas were cloned using 
lxHT (hypoxanthine and thymidine) supplemented medium contain feeder layer. The cells were 
diluted to approximately 5 cells/well, 1 cell/well and 0.5 cell/well. The cells of each concentration 
dispensed in 32 wells of 96 well microculture plate. After two weeks the wells which appear to 
contain one clone were screened by ELISA.
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3.2.8 Ascitic fluid production
Monoclonal antibodies were produced in large amounts from ascitic fluid in mice primed with Non­
ulcerative Freund's Adjuvant (NUFA), to enhance the local inflammatory reaction at the site of 
injection. Three female Balb/c mice at 25 weeks old were primed with 0.3 ml NUFA. 1x10^ 
cells/mouse were injected interaperitoneally (i.p.) 3 days after priming. After 15 days the ascites 
fluid was collected using a syringe and a needle from the distended abdomen.
3.2.9 Antibodies purification
A. Protein A method
Protein A was used to purify the mouse monoclonal antibodies. It is synthesised by staphylococcus 
aureus and binds to the Fc region of most immunoglobulin molecules.
A 10ml column was packed with lg  protein A. The column was then washed with 50 ml 0.03M 
phosphate buffered saline, pH 7.4. Ascitic fluid (0.2ml) was then applied and allowed to pass into 
the column. The column was then washed with 0.3M phosphate buffer saline, pH 7.4 until no 
detectable protein was measured in the effluent. 0.1M citrate/phosphate buffer, pH 3.5 was then 
applied to the column and 2 ml fractions were collected. The fractions were analysed for 
immunological activity using the modified indirect ELISA, see section 3.2.4.
B. Fast protein liquid chrom atography (FPLC) method
The fast protein liquid chromatography is a new technique which has been used to purify the 
monoclonal antibodies.
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The mono-Q column was primed with 0.02M Tris/Hcl, pH 7.6 . Ascitic fluid 0.1 ml was initially 
passed through a 0.22 |im  millipore filter and injected into the column via a loop. A stepped 
gradient had been programmed into the machine using two buffers;
I. 0.02M Tris /  HC1, pH 7.6 .
n. 0.02M Tris /  HC1 containing 0.05 M NaCl.
The first 6 minutes buffer ratio was 90% I and 10% II were run through the column. Over a period 
of 30 minutes the buffer, (II), was increased to 45% and this was maintained for 5 minutes. This 
was then increased to 100% within 5 minutes and this was maintained for further 15 minutes. After 
the run was completed, the buffer, (II), concentration was decreased to 10%. Two ml fractions 
were collected. The computer chart indicated the fractions which contained the immunoglobulin. 
The fractions were analysed for the immunological activity using the modified indirect ELISA, see 
section 3.2.4 .
C. Large scale purification method
Monoclonal antibodies were purified using saturated ammonium sulphate. Saturated ammonium 
sulphate was added slowly via a burette to the culture supernatants (one volume saturated 
ammonium sulphate to two volumes culture supernatant). The solution was then centrifuged at 
3000 g for 30 mins. The pellet was resuspended in 0.03M phosphate buffer, pH 7.4 and dialysed 
against the same buffer. The purified antibodies were analysed for immunological activity using the 
modified indirect ELISA, see section 3.2.4. The antibodies were then freeze-dried.
3.2.10 Polyacrylamide slab gel electrophoresis with sodium dodecyl sulphate
The method of Laemmli (1970), was used to analyse the purified monoclonal antibodies 
fractions. A range of molecular weight standards were used so that the immunoglobulin types
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could be investigated. The separation was carried out on slab gel (160x160x2 mm) consisting of a 
stacking gel 5% acrylamide over laid on a separation gel 10% acrylamide. The samples and the 
standards (50}ig/20|il protein) were stained with bromophenol blue then placed in a boiling water 
bath for 3 minutes to denaturate the samples. They were then cooled and applied to the appropriate 
wells in the stacking gel.
The gel was placed into the electrophoresis tank which contained the electrophoresis buffer, 0.25M 
Tris-1.92M glycine buffer, pH 8.3. The electrodes were connected to the power supply with the 
anode to the lower chamber and the cathode in the upper. The gel was electrophoresed at constant 
voltage (200 volts) until the blue dye reached the bottom of the gel. The power was switched off. 
The cassette was removed from the tank and the plates carefully separated. The stacking gel was 
cut off and the gel stained. The gel was stained in 0.1% coomassi brilliant blue R-250 in 
methanol:distilled water: glacial acetic acid (ratio 5:5:2) for 1 hour. The gel was then destained in 
several changes of the destaining solution which was methanol:distilled watenglacial acetic acid 
(ratio 5:5:2).
3.2.11 Immunoglobulin class and subclass determ ination
The immunoglobulin class and subclass secreted by the hybrids were determined by Ouchterlony 
double immunodiffusion technique, modified indirect ELISA (Figure 3.2) and modified four 
antibody layers-ELISA (Figure 3.3).
A. Ouchterlony double immunodiffusion technique
Square glass slides were precoated with a small volume of 2% agarose gel in Tris-barbitone buffer, 
pH 8.6 and were allowed to dry at room temperature. The slides were then coated with 8 -10  ml 
(1% agarose gel) and allowed to dry. When the gel has hardened wells were punched with a
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template (LKB inc., Sweeden). The well sizes were such that they held 5|il sample volume. The 
sheep anti-mouse immunoglobulin antisera (Serotec Ltd., U.K.) anti IgA, IgM and IgG class and 
anti IgGl, IgG2a, IgG2b and IgG3 subclass were placed in the wells arranged around the central 
well. They were used at concentration 1:10. Either neat supernatant (10|il) or diluted ascitic fluid 
(1:50) were placed in the centeral wells. The slides were then incubated in a moist box at room 
temperature for 2 - 3 days. Precipitation lines were observed. The slides were washed in 0.15M 
phosphate buffer saline, pH 7.4 for about 2 hours to wash away the unreacted protein. The slides 
were pressed dry by placing several layers of filter paper on top of the gel and placing an even 
weight on top. When the agarose was completely dry, the slides were placed for 10 minutes in a jar 
filled with 0.1% coomassie brilliant blue in methanol:distilled water:glacial acetic acid (ratio 
5:5:2). The gel was destained by methanohdistilled watenglacial acetic acid (ratio 5:5:2).
B. Modified indirect ELISA
I. GLP-l(7-36) monoclonal antibodies
The soft plates were coated with GLP-l(7-36) at a concentration of l|ig/ml 0.1 M bicarbonate 
carbonate buffer, pH 9.6 (200 p.l/well). The plates were incubated overnight at 4°c in a moist box. 
Next day the plates were washed 4 times with PBSGT as in section 3.2.4, all further dilution and 
washing were carried out using this buffer. The monoclonal antibodies were added to the assay 
wells (200pl/well) in duplicate and the plates were then incubated for 2 hours at 37 °c in a moist 
box. The wells were then washed as before. The sheep immunoglobulin class and subclass 
antisera (1:500) were added to the appropriate wells (200|il/well). The plates were then incubated 
for 2 hours at 37°c in a moist box. Peroxidase- labelled donkey anti-sheep serum was added to the 
plates (200}il/well) for 2 hours at 37°c. The plates were washed again and (150|il/well) substrate 
solution (orthophenylenediamine) was added to all wells . The plates were then incubated at 37 °c
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for 30 minutes in a moist box. The reaction was then stopped by adding 50p,l of 2.5M sulphuric 
acid and the wells read on automated ELISA reader at a wavelength of 490 nm.
II. N-terminal fragment monoclonal antibodies
The assay protocol was similar to section 3.2.11, B , I, except, the ELISA plates were coated with 
l|ig/ml N-terminal fragment.
III. C-terminal fragment monoclonal antibodies
The assay protocol was similar to section 3.2.11, B, I, except, the ELISA plates were coated with 
1 fig /  ml C-terminal fragment.
C. Modified four antibody layers - ELISA
I. GLP-l(7-36) monoclonal antibodies
The soft plates were coated with 40 Hg/ml affinity purified donkey anti-mouse serum diluted in
0.1M bicarbonate carbonate buffer, pH 9.6 (200|il/well). The plates were incubated for 2 hours at 
37°c in the moist box. The plates were washed 4 times with PBSGT as in section 3.2.4, all further 
washing and dilutions were carried out with this buffer. The monoclonal antibodies were added to 
the assay wells (200jil/well) in duplicate and the plates were then incubated overnight at 48c in a 
moist box. Next day the plates were washed as before. The sheep anti-mouse immunoglobulin 
class and subclass antisera (1:5000) were added to the appropriate wells (200|il/well). The plates 
were then incubated for 2 hours at 37 °c in a moist box. Peroxidase-labelled donkey anti-sheep 
serum was added to the plates (200pl/well) for 2 hours at 37°c. The plates were washed again and 
(150|il/well) substrate solution (orthophenylenediamine) was added to all wells. The plates were
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then incubated at 37°c for 30 minutes in a moist box. The reaction was then stopped by adding 
50|il of 2.5M sulphiric acid and the wells read on automated ELISA reader at a wavelength of 490 
nm.
II. N-terminal fragment monoclonal antibodies
The assay protocol was similar to that discribed in section 3.2.11, C, I, except, the monoclonal 
antibodies were anti N-terminal fragment antibodies.
III. C-terminal fragment monoclonal antibodies
The assay protocol was similar to that discribed in section 3.2.11, C, I, except, the monoclonal 
antibodies were anti C-terminal fragment antibodies.
3.2.12 Monoclonal antibodies dilution and displacement curves
The antigen concentrations were varied in the range 0 - 1  |ig/ml to optimise the coating antigen 
concentration. Once an optimum coating antigen concentration (1 |ig/ml) had been obtained then the 
monoclonal antibodies dilution and displacement curves were produced for each monoclonal 
antibody using the modified indirect ELISA, see section 3.2.4 . The concentration of conjugated 
or free peptides used to displace the antibodies was 10 ng/ml.
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3.2.13 M onoclonal antibodies specificity
A. G LP-l(7-36) monoclonal antibodies
A modified indirect ELISA was used to assess the degree of crossreactivity of anti GLP-1(7-36) 
monoclonal antibodies with GLP-1(1-37) and the two peptide fragments, see section 3.2.4,A. The 
maximum concentration of peptides coated onto the ELISA plates was lpg/ml. The degree of 
cross-reactivitywas calculated as a percentage of the amount of specific antigen divided by the 
amount of cross-reactant at 50% of the maximum optical density.
B. N-term inal fragm ent monoclonal antibodies
The modified indirect ELISA was used to assess the degree of crossreactivity of anti N-terminal 
fragment monoclonal antibodies with GLP-l(7-36), GLP-l(l-37) and the C-terminal fragment, see 
section 3.2.4, B . The maximum concentration of peptides coated onto the ELISA plates was 
1 jig/ml.
C. C-term inal fragm ent monoclonal antibodies
The modified indirect ELISA was used to assess the degree of crossreactivity of anti C-terminal 
fragment monoclonal antibodies with GLP-1(7-36), GLP-1(1-37) and the N-terminal fragment, see 
section 3.2.4, C . The maximum concentration of the peptides coated onto the ELISA plates was 
lpg/ml.
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Figure 3.2 . The modified indirect enzyme linked immunosorbent assay (ELISA).
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Figure 3.3 . The modified four antibodies layers enzyme linked immunosorbent assay (ELISA).
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3.3 RESULTS
3.3.1 Investigation of NSI myeloma cells; NSI growth characteristics
Figure 3.4 demonstrate the exponential growth phase and viability of NSI myeloma cells. The 
number of live cells in the culture and hence the cell viability rapidly declined when the cell density 
was in excess of 0.8x10^ cells/ml. The cultures were maintained between 2x10^ cells/ml and 
4x10^ cells/ml. Figure 3.5 show the NSI cells in suspension culture.
3.3.2 Cell fusion experiments
The supernatants were initially screened using the indirect ELISA, see section 3.2.4 . The positive 
hybridomas were rescreened using the same method. Four cell lines producing anti GLP-1(7-36), 
three cell lines producing anti N-terminal and seven cell lines producing anti terminal fragment 
were obtained (Table 3.2).
3.3.3 Polyacrylamide slab gel electrophoresis with sodium dodecyl sulphate
The eletrophoresed, protein A purified, monoclonal antibodies samples are shown in Figure 3.6A. 
The heavy and light chains were observed two clear bands with no external effect from other 
proteins presented in the ascitic fluid. The band positions were also confirmed by the mobility of 
the samples in relation to the standards. The electrophoresed FPLC purified monoclonal antibodies 
samples are shown in figure 3.6B. This method produced an impure product indicating that FPLC 
is not completely efficient at removing all contaminating proteins from the monoclonal antibodies.
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Figure 3.4 . The NSI growth characterisation; the average cell numbers from 4 cultures 
were plotted.
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Figure 3.5 . The NSI cells in suspension culture.
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Table 3.2 . The effect of various methods of immunisation on the results of cell fusion 
experiments
Antigen GLP-1
(7-36)
N-terminal
fragment
C-terminal
fragment
Immunisation
method
A B A B D A C D
No. of fusions 2 3 2 3 1 2 2 1
No. of fusion 
wells
276 309 238 357 95 240 240 95
No. of fusion 
wells with hybrids
32 130 — — — — — —
Wells with 
hybrids %
11.6 42.1 — — — — — —  .
Positive culture wells 
after screening
1 15 12 22 11 16 39 11
Cell lines cloned by 
limiting dilution
0 4 2 0 1 0 0 6
Cell lines frozen in the 
liquid nitrogen
0 4 2 0 1 0 0 7
Positive wells% 3.1 11.5 ___ __ _ _ _ — - — -
Specific efficiency % 27.0 27.4 5.0 6.2 11.6 6.7 16.3 11.6
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Figure 3.6 . SDS-Page electrophoresis of purified mouse monoclonal antibodies by 
A- Protein A method
B- Fast protein liquid chromatography method
(a) F4/15 anti GLP-1(7-36) (unpurified)
(b) F4/15 anti GLP-1(7-36) (purified)
(c) G 12/16 anti GLP-1(7-36) (purified)
(d) D3/9 anti N-terminal fragment (purified)
(e) C5/3 anti C-terminal fragment (purified)
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3.3.4 Antibodies class and subclass
Table 3.3 shows the result obtained by ouchterlony technique.
Table 3.3 . The ouchterlony immunodiffusion analysis of the produced monoclonal antibodies;
+ = precipitation lines
-= no precipitaion lines was formed
Cloned 
cell line
Positive
wells
Peptide
Anti-mouse immunoglobulin
IgM IgA IgG
G1 G2a G2b G3
B2/3 G l/15 GLP-1 — ------- -------- — — +
F4/15 (7-36) — — -------- — + —
G12/16 — ------- ------- — — +
C4/2 E9/17 — ------- ------- — — +
D2/2 A 4/9 — ------- -------- — + — -
CIO/9 — ------- - - - — + —
Cl 1/9 N-terminal — ------- -------- +
D 3/9 fragment — ------- -------- — + —
D 8/9 — ------- - - - - - - + —
A12/10 — + ------- — — —
C7/10 — + -------- — — —
D3/10 — + -------- — — —
D3/5 B 7/1 — ------- -------- + —
E 4 /1 — ------- -------- + —
E 8/1 C-terminal — - — - -------- + — —
E12/1 fragment — ------- - - - + — —
B4/4 Cl 1/ 3 ------- -------- — +
C 5 /3 — ------- -------- — + —
D 7 /4 — ------- + — — —
B6/3 B7 /13 — ------- -------- + — —
D3/13 — ------- -------- + — —
B l/14 — ------- -------- + — —
Bl/3 D3/20 — ------- -------- + — —
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3.3.5 Antibodies dilution and displacement curves
I. Mice antisera
A. GLP-l(7-36) antiserum
Figure 3.7A shows the effect of different coating antigen concentrations on the optical density 
reading using one antibody dilution (1:100). Figure 3.7B show the mouse antiserum anti GLP- 
1(7-36) dilution curve using the optimised coating antigen concentration (Ipg/ml). No 
displacement was observed.
B. N-Terminal fragment antiserum
Figure 3.7C shows the effect of different coating antigen concentrations on the optical density 
reading using one antibody dilution (1:100) . Figure 3.7D shows the antiserum anti N-terminal 
fragment dilution curve using the optimised coating antigen concentration (lpg/m l). No 
displacement was observed.
C. C-terminal fragment antiserum
Figure 3.7E shows the effect of different coating antigen concentrations on the optical density 
reading using one antibody dilution (1:100). Figure 3.7F shows the antiserum anti C-terminal 
fragment dilution curve using the optimised coating antigen concentration (1 fig/ml). No 
displacement was observed.
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Figure 3.7 . The mice antisera dilution curves;
A. The effect of different GLP-1(7-36) concentrations on GLP-1(7-36) antiserum.
B. The GLP-1(7-36) antiserum dilution curves.
C. The effect of different N-terminal fragment concentrations on N-terminal fragment antiserum.
D. The N-terminal fragment antiserum dilution curve.
E. The effect of different C-terminal fragment concentrations on C-terminal fragment antiserum.
F. The C-terminal fragment antiserum dilution curve.
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II. M onoclonal antibodies
A. G LP-l(7-36) monoclonal antibodies
Figure 3.8A shows the effect of different coating antigen concentrations on the optical density 
reading using one antibody dilution (1:500). After optimising the coating antigen concentration, the 
dilution curves for the monoclonal antibodies were obtained . Figure 3.8B shows the result of one 
cell line anti GLP-1(7-36) because the rest of the cell lines behaved in the same way. No 
displacement was observed.
B. N-term inal fragm ent monoclonal antibodies
Figure 3.8C shows the effect of different coating antigen concentrations on the optical density. 
Figure 3.8D shows the dilution curve of anti N-terminal fragment monoclonal antibody using the 
optimised coating antigen concentration (1 |ig/ml). No displacement was observed.
C. C-term inal fragm ent monoclonal antibodies
Figure 3.8E shows the effect of different coating antigen concentrations on the optical density 
reading. Figure 3.8F shows the dilution curve of anti C-terminal fragment monoclonal antibody 
using the optimised coating antigen concentration (lpg/ml). No displacement was observed.
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Figure 3.8 . The mice monoclonal antibodies dilution curves;
A. The effect of different GLP-1(7-36) concentrations on GLP-1(7-36) monoclonal antibody (Cell 
lineF4/15).
B. The GLP-1(7-36) monoclonal antibody dilution curve (Cell line F4/15).
C. The effect of different N-terminal fragment concentrations on N-terminal fragment monoclonal 
antibody (Cell line D3/9).
D. The N-terminal fragment monoclonal antibody dilution curve (Cell line D3/9).
E. The effect of different C-terminal fragment concentrations on C-terminal fragment monoclonal
antibody (Cell line C5/3).
F. The C-terminal fragment monoclonal antibody dilution curve (Cell line C5/3).
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3.3.6 Antibodies specificity
I. Mice antisera
A. GLP-l(7-36) antiserum
Mouse GLP-1(7-36) antiserum was assessed against GLP-1 (1-37), the N-terminal frgment and 
the C-terminal fragment using a range of 0 - 1 pg/ml of coating antigens concentrations (Figure 
3.9A). The antiserum showed 50% crossreactivity with GLP-1 (1-37) and the C-terminal fragment 
but no crossreactivity with the N-terminal fragment was observed.
B. N-terminal fragment antiserum
Mouse N-terminal fragment antiserum was assessed against GLP-1 (7-36), GLP-1(1-37) and the 
C-terminal fragment using a range of 0 - lfig/ml of coating antigens concentrations (Figure 3.9C). 
The antiserum showed 50% crossreactivity with the C-terminal fragment but no crossreactivity 
with both GLP-1 (7-36) and GLP-1(1-37) was observed.
C. C-terminal fragment antiserum
Mouse C-terminal fragment antiserum was assessed against GLP-l(7-36), GLP-l(l-37) and the 
N-terminal fragment using a range of 0 - l(ig/ml of coating antigens concentrations (Figure 3.9E). 
The antiserum showed 25.2% crossreactivity with GLP-1 (7-36) and 50 % with the N-terminal 
fragment but no crossreactivity with GLP-1 (1 -37) was observed.
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II. Monoclonal antibodies
A. GLP-l(7-36) monoclonal antibodies
Three different cell lines producing anti GLP-1(7-36) antibodies were used to produce ascitic 
fluid. The monoclonal anti GLP-l(7-36) antibodies were assessed against GLP-l(l-37), the N- 
terminal fragment and the C-terminal fragment using a range of 0 - l|ig/ml of coating antigens 
concentrations. Figure 3.9B shows one of the monoclonal antibodies crossreactivity results. The 
cell line showed 25.2% crossreactivity with the N-terminal fragment but no crossreactivity with 
GLP-1(1-37) or the C-terminal fragment was observed. The other 2 cell lines showed similar 
results.
B. N-terminal fragment monoclonal antibodies
One anti N-terminal fragment cell line was used to produce ascitic fluid. The monoclonal antibody 
was assessed against GLp-1 (7-36), GLP-1(1-37) and the C-terminal fragment using a range of 0 - 
lfig/ml of coating antigens concentrations. Figure 3.9D shows the crossreactivity results. The 
antibodies showed 12.6% crossreactivity with both GLP-l(7-36) and GLP-1 (1-37) and 50% 
crossreactivity with the C-terminal fragment.
C. C-terminal fragment monoclonal antibodies
Two cell lines anti C-terminal fragment were used to produce ascitic fluid. The monoclonal 
antibodies were assessed against GLP-1(7-36), GLP-1(1-37) and the N-terminal fragment using a 
range of 0 - ljig/ml of coating antigens concentrations. Figure 3.9F shows the crossreactivity
9 8
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results. The cell line showed 25.2% crossreactivity with GLP-l(7-36), 12.6% with GLP-l(l-37) 
and 50% with the N-terminal fragment.
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Figure 3.9 . The mice antibodies specificity;
A. The GLP-1(7-36) antiserum.
B. The GLP-1 (7-36) monoclonal antibody (Cell line F4/15).
C. The N-terminal fragment antiserum.
D. The N-terminal fragment monoclonal antibody (Cell line D3/9).
E. The C-terminal fragment antiserum.
F. The C-terminal fragment monoclonal antibody (Cell line C5/3).
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3.4 DISCUSSION
A high specific efficiency for cell fusion experiments is highly desirable in all monoclonal antibody 
production. Daily immunisation of the donor animals for 4 days before fusion with large amounts 
of immunogen have increased the specific efficiency (Shibier et al., 1988). However, the PEG 
used was 1500 MW not 6000 MW as stated in the paper by Shibier et al. 1988. When an 
identical protocol was followed immunising mice with the N- and C-terminal fragments a low 
specific efficiency was observed. Immunisation with only small amounts of conjugated GLP-1 
(7-36) resulted in the most successfull fusion. Different immunisation protocols can be used to 
increase the specific efficiency but the most important criteria appears to be the immunogenicity of 
the antigens. An increase in the specific efficiency which depends on the immunisation schedule 
been optimised for fusion experiments is of great importance in order to generate the largest 
possible number of specific blast and/or plasma cells (Stahli et al., 1980). The high cost of 
GLP-1 (7-36) has prevented the use of the daily immunisation with large amounts. An interesting 
observation was that mice immunised with the small peptides had similar or lower titre than GLP-1 
(7-36) immunised mice. Campbell (1984) reported that the antiserum titre elicited has undoubted 
relevance to the likelihood of specific hybridoma production.
ELISA offers a number of advantages, the labelled reagents used are stable and easy to store for a 
long time without loss of activity. Multi well microtitre plates can be used as solid phase. Most 
ELISA reagents are commercially available. ELISA was chosen to screen for the positive 
hybridomas in order to develop an enzyme immunoassay to measure the presence of GLP-1 in the 
plasma. There were several reasons why anti N- and C-terminal peptides monoclonal antibodies 
were produced. Firstly, GLP-1 (7-36) is very expensive and secondly, the production of anti N- 
and C-terminal fragments monoclonal antibodies may enable development of a two site sandwich 
ELISA. However, attempts to develop such an assay were unsuccessful. The modified indirect
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ELISA proved successful but all the monoclonal antibodies appeared to have greater affinity for 
the conjugated peptide which was coated onto the ELISA plate than the peptide in solution. A 
competitive GLP-1 (7-36) ELISA may overcome this problem. GLP-1 (7-36) can be chemically 
coupled to the enzyme peroxidase i.e. mixed anhydride method (Erlanger et al., 1957) and 
periodate method (Beyzavi et al., 1987) or biotin i.e. N-hydroxy-succinimide ester method 
(Anderson et al., 1964b). In the competetive ELISA the solid phase will be coated with 
donkey anti mouse affinity purified antibody. Then monoclonal anti GLP-1 antibody will be 
added as the second layer in the assay. Finally peroxidase labelled GLP-1 (7-36) will be 
competing with unlabelled GLP-1 present in the standard /  sample.
The lack of displacement of the antisera prevented the develpoment of an assay. Cross reactivity 
could therefore not be assessed using the conventional methodology. The GLP-1 (7-36) 
monoclonal antibodies showed no measurable crossreactivity with GLP-1 (1-37) or the C-terminal 
fragment. However, these monoclonal antibodies showed crossreactivity with the N-terminal 
fragment. Anti GLP-1 (7-36) monoclonal antibodies can be used to develop an ELISA and may 
therefore be potentially usefull in determining the levels of physiologically insulinotropic peptide, 
truncated GLP-1 (7-36). The monoclonal antibodies raised against the N- and C-terminal fragments 
showed cross-reactivity with both GLP-1 (7-36) and GLP-1 (1-37). The assay will help for the 
first time to determine the circulating level of the whole peptide GLP-1 (1-37) and the truncated 
GLP-1 (7-36).
The monoclonal anti N-terminal fragment antibodies showed crossreactivity with the C-terminal 
fragment. Moreover, the monoclonal anti C-terminal fragment showed crossreactivity with the N- 
terminal fragment. These crossreactivities could be due to the fact that, the monoclonal antibodies 
recognised the bridge which connects the carrier protein to the peptide. This problem may be 
overcome by using a different method of conjugating the N- and C-terminal fragments to a carrier 
protein such as carbodiimide conjugation method were the carrier protein more likely to be coupled 
to the C-end of the peptides. The addition of a spacer group between the peptides and the protein
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may enable development of displacable antisera. Since the peptide may be more easily recognised 
by circulating lymphocytes and the hapten will be separated from the large molecular weight 
protein. Aherne et al., (1976), introduced a 4 carbon link between the hapten and the carrier 
using the reagent N(4-bromobutyl)phthalimide and they suggest that this was responsible for the 
increased immunogenicity of their conjugate.
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ANTISERA PRODUCTION
1 0 5
ANTISERA PRODUCTION
4.1 GENERAL INTRODUCTION
Antibodies with high avidity and specificity are required when developing immunoassay with high 
sensitivity and low crossreactivity. Radio and enzyme immunoassay techniques have played an 
important role in meeting the immunoassay development demands. Several modifications of the 
ELISA procedures have been described for the detection of antigens (K em eny and  
Challacombe, 1988). These include as for RIA procedure, the competitive type of assay and the 
non competetive binding assay (Hunter and Corrie, 1983 and Edw ards, 1985).
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4.2 MATERIALS AND METHODS
4.2.1 Peptides conjugations
A. GLP-l(7-36) - egg albumin/keyhole limpet hemocyanin conjugations
GLP-1(7-36) was conjugated to egg albumin/keyhole limpet hemocyanin using the method 
described in chapter 3, section 3.2.2,A .
B. N-terminal fragment-egg albumin/keyhole limpet hemocyanin conjugations
N-terminal fragment was conjugated to egg albumin/keyhole limpet hemocyanin using the method 
described in chapter 3, section 3.2.2,B .
C. C-terminal fragment-egg albumin/keyhole limpet hemocyanin conjugations
C-terminal fragment was conjugated to egg albumin/keyhole limpet hemocyanin using the method 
described in chapter 3, section 3.2.2,C.
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4.2.2 Im m unisation
The conjugated peptides plus BCG were mixed with Non-Ulcerative Freud's Adjuvant (NUFA), 
(Morris), as described in chapter 3, section 3.2.3 .
A. GLP-l(7-36) - keyhole limpet haemocyanin conjugate im m unisation
Two halflop rabbits were immunised with 200 |ig of conjugated GLP-l(7-36) (100|ig/rabbit). 
They were immunised intradermally into 40 sites on the neck and the back. After 9 months a 
booster injection was given. Two further boosts were given with 3 months interval between them.
B. N-term inal fragm ent-keyhole limpet haemocyanin conjugate im m unisation
Two sheep, a Suffolk and a soay, were immunised with 200jig of conjugated N-terminal fragment 
(100|ig/sheep). They were immunised intramuscularly into 8 sites on the upper legs. After 2 
months a booster injection was given. Two further boosts were given with 5 months interval 
between them.
C. C-term inal fragment-keyhole limpet haemocyanin conjugate im m unisation
Two sheep, a Suffolk and a soay, were immunised with 200|ig of conjugated C-terminal fragment 
(lOOpg/sheep) using the same method described above in 4.2.2,B .
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4.2.3 Screening
4.2.3.1 Indirect enzyme linked im m unosorbant assay (ELISA)
A. Antisera dilution and displacement curves
I. R abbit G LP-l(7-36) antiserum
Soft plates were coated with 1 |ig/ml GLP-l(7-36)-egg albumin conjugate diluted in 0.1M 
bicarbonate carbonate buffer, pH 9.6 and incubated overnight at 4°c in a moist chamber. Next day 
the plates were washed four times with PBSGT (see chapter 3, section 3.2.4.A). The rabbit GLP- 
1(7-36) antisera diluted 1:1000 to 1:128000 were added to the appropriate assay wells (200|il/well) 
in duplicate and the plates were then incubated for 2 hours at 37°c in a moist chamber . After 
washing the plates as before the peroxidase-labelled donkey anti-rabbit serum (HP/D/19 VIIB-3) 
was added to all wells (200|il/well) and incubated for 2 hours at 37°c in moist chamber. The plates 
were washed again and substrate solution (150|il/well) was added to all wells. The plates were 
then incubated at 37°c for 30 minutes in a moist chamber. The reaction was then stopped by adding 
50 |il of 2.5M sulphuric acid and the plates were read on automated ELISA reader at a wavelength 
of 490 nm.
At the same time a displacement curve was set up. This will help to investigate the antibody 
affinity. Diluted antiserum was incubated with 10 ng/ml GLP-1(7-36) overnight at 4°c. The 
following day the plates were washed as above. The preincubated antiserum was added to the 
appropriate wells and incubated for 2 hours at 37°c. The protocol was then as described above.
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II. Sheep N-terminal fragment antiserum
The assay procedure were the same as before in section 4.2.3,A except that the plates were coated 
with N-terminal fragment-egg albumin conjugate (1 |ig/ml) and peroxidase-labelled donkey anti­
sheep serum (HP/D/48XIIIC-4) was used.
At the same time a displacement curve was set up using the N-terminal fragment (lOng/ml). The 
protocal was similar to that described in section 4.2.3.1, A-I.
III. Sheep C-terminal fragment antiserum
The assay procedure were the same as before in section 4.2.3,A except that the plates were coated 
with C-terminal fragment-egg albumin conjugated }ig/ml) and the peroxidase-labelled donkey anti­
sheep antiserum (HP/D/48XIIIC-4) was used.
At the same time a displacement curve was set up using C-terminal fragment (lOng/ml). The 
protocol was similar to that described in section 4.2.3.1,A -I.
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B. A ntisera specificity
I. Rabbit G LP-l(7-36) antiserum
The rabbit GLP-1(7-36) antiserum specificity was assessed against the relevant peptides, GLP- 
1(1-37), N- and C-terminal fragment. The assay procedures were as described in section
4.2.3.1,A-I except the plates were coated with GLP-1 (1-37), N- or C-terminal fragments at a 
maximum concentration of (l|ig/ml).
II. Sheep N-term inal fragm ent antiserum
The sheep N-terminal fragment antisera specificity was assessed against the relevant peptides, 
GLP-l(7-36), GLP-1 (1-37) and the C-terminal fragment. The assay procedures were as described 
in section 4.2.3.1,A-II except the plates were coated with GLP-l(7-36), G LP-l(l-37) or C- 
terminal fragment at a maximum concentration of (lpg/ml).
III. Sheep C-terminal fragm ent antiserum
The sheep C-terminal fragment antisera specificity was assessed against the relevant peptides, 
GLP-1(7-36), GLP-1 (1-37) and the N-terminal fragment. The assay procedures were as described 
in section 4.2.3.1,A-III except the plates were coated with GLP-l(7-36), G LP-l(l-37) or N- 
terminal fragment at a maximum concentration of (l|ig/ml).
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4.2.3.2 Radio Immunoassay (RIA)
A. GLP-l(7-36) iodination methods
I. Chloramine T method
5 pg GLP-1(7-36) was dissolved in 25 pi 0.4M phosphate buffer, pH 7.4 in a small autoanalyser 
cup. 18.5 MBq (0.5 mci in 5 pi aliquot) of N a ^ ^ i  was added to the peptide. Add 200 pg 
chloramine T which dissolved in 5 pi 0.04M phosphate buffer, pH 7.4 . After 5 seconds, 48 pg of 
sodium metabisulphate which dissolved in 50pl 0.04M phosphate buffer, pH 7.4 and 500 pg 
potassium iodide which dissolved in 50 pi of the same buffer were added. The reactants were 
mixed throughout this process with small magnetic flea. The reactants were then loaded on to the 
sephadex G15 15cm x 0.5cm. The iodinated GLP-1 (7-36) was then eluted with 0.04M phosphate 
buffer, pH 7.4 containing 0.5 % BSA. The purified tracer was aliquoted and stored at 20°c. Two 
other iodinations were carried out allowing the reactants to react for 10 and 15 seconds before 
adding sodium metabisulphate.
II. Iodogen method
20 pg of iodogen (1,3,4,6- tetrachloro -3a, 6a-diphenyl-glycouril) was dissolved in analar 
dichloromethane in the bottom of a small polypropylene tube and allowed to dry. During the 
iodination, 5pg GLP-1(7-36) was dissolved in 25pl 0.4M phosphate buffer, pH 7.4 . 18.5 MBq 
(0.5 mci in a 5 pi aliquot) of N a ^ I  was added to the peptide. The reactants were mixed by gentle 
shaking of the tube for 5 minutes, then 240 pg sodium metabisulphate dissolved in 200 pi 0.04M 
phosphate buffer, pH 7.4, was added to stop the reaction. The reactants were then loaded onto the 
sephadex G15 column as described before in the Chloramine T iodination method. Timing studies
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were also carried allowing the reactants to react for 10 and 15 minutes before adding sodium 
metabisulphate.
B. G L P -l(l-37) iodination methods
I. Chloram ine T method
5 fig GLP-1(1-37) was iodinated and a timing studies were also carried out as described in section
4.2.3.2,A-I .
II. Iodogen m ethod
5 jig GLP-l(l-37) was iodinated and a timing studies were also carried out as described in section
4.2.3.2,A-II .
C. N-term inal fragm ent iodination method
5 fig N-terminal fragment was iodinated using the iodogen method and the reactant were allowed to 
react for 10 minutes as described before in section 4.3.2,A -II.
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D. Antisera and displacement curves
I. Rabbit GLP-l(7-36) antiserum
The antisera dilutions were made up in 0.04M phosphate buffer, pH 7.4 containing 0.5 % bovine 
serum albumin (BSA). To a series of LP3 tubes the antisera diluted in the assay buffer were added 
in duplicate. Assay buffer and diluted labelled GLP-1(7-36) was added to the tubes which were 
vortex and incubated for overnight at 4°c. The donkey anti-rabbit immunoglobulin (D/15-XB) and 
normal rabbit serum were diluted in assay buffer and added to the assay tubes followed by the 
addition of 12% polyethyleneglycol (PEG). The tubes were vortex and incubated for 2 hours at 4°c 
before centrifugation. The tubes were then spun for 30 minutes at 3000 rpm in a refrigerated 
centrifuge. The supernatants were aspirated and the pellet counted in a multigamma counter (Table 
4 .1 ).
In the same time a displacement curve is setup to look at the antiserum affinity. lOng/ml cold GLP- 
1 (7-36) were used to displace the antibody from the tracer (Table 4.1).
II. Sheep N-terminal fragment antisera
The assay was setup the same way as described before in section 4.2.3.2,D-I except using sheep 
N-terminal fragment antisera and donkey anti-sheep immunoglobulin (D48). Displacement curves 
were setup with cold N-terminal fragment (lOng/ml), (Table 4.1).
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Table 4.1 The antiserum and displacement protocols.
Dty 1 Day 2 Day 3
Tube Buffer Antiserum Labd Cold Label Dab 12% PEG
Ml Ml Ml peptide
Ml
Ml Ml Ml
Tool — — 100 — — — —
NSB 200 — ' 100 — — — —
Zero 100 100 100 — — — —
Displacement 50 100 — 50 100 100 100
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4.2.4 A ntisera purification
A. Rabbit GLP-l(7-36) antiserum
The anion exchange chromatography method was used to purify the antiserum. The diethyl 
aminoethyl (DEAE) Zetaprep 15 ion exchange disc (LKB-Sweden) was primed with 75 ml of
0.01M phosphate buffer, pH 6.4 , 2 ml of the rabbit antiserum were diluted 1:10 by the same 
buffer. After passing the 20 ml of diluted serum, 30 ml of the same buffer were passed through the 
disc. Upon the addition of the antiserum to the disc, ten fractions were collected in 5 ml glass 
containers. The absorbance of each fraction was read at 280 nm using the Cecil CE292 digital 
ultraviolet spectrophotometer (Cecil instruments Ltd. milton, Cambridge, U.K. ). The fractions 
displaying peak absorbance reading were pooled and the total immunoglobulin ( mg/ml) content 
was calculated. lOOfil/lOml Of 0.2% thiomersal (Sigma, U.K.) was then added to the pooled 
fractions. The disc was then regenerated using 75 ml of 1M acetic acid followed by 75 ml of
0.01M phosphate buffer, pH 6.4 .
B. Sheep N-term inal fragm ent antiserum
The antiserum was purified using the same method as described before in section 4.2.4,A .
C. Sheep C-terminal fragm ent antiserum
The antiserum was purified using the same method as described before in section 4.2.4,A .
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4.3 RESULTS
4.3.1 Screening
A. Indirect enzyme linked im m unosorbant assay (ELISA)
A.l A ntisera specificity
I. R abbit GLp-l(7-36) antiserum
Figure 4.1 A shows the ELISA results of the rabbit GLP-1 (7-36) antiserum crossreactivity with 
the relevant peptides. The antiserum showed 12.6% crossreactivity with GLP-1 (1-37). However, 
slight crossreactivity with the N- and C-terminal fragment was observed.
II. Sheep N-terminal fragm ent antiserum
Figure 4.IB shows the ELISA results of the sheep N-terminal fragment antiserum crossreactivity 
with the relevant peptides. The antiserum showed 12.6% crossreactivity with GLP-1 (7-36) and 
GLP-1(1-37), and, 6.3% crossreactivity with the C-terminal fragment.
III. Sheep C-terminal fragm ent antiserum
Figure 4.1C shows the ELISA results of the sheep C-terminal fragment antiserum cross-reactivity 
with the relevant peptides. The antiserum showed 6.3% crossreactivity with the N-terminal 
fragment but slight crossreactivity with GLP-1 (7-36) and GLP-l(l-37) was observed.
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Figure 4.1 . The antisera specificity;
A. The rabbit GLP-1 (7-36) antiserum.
B. The sheep N-terminal fragment antiserum.
C. The sheep C-terminal fragment antiserum.
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B. Radioimmunoassay
I. GLP-l(7-36) iodination
Figures 4.2 and 4.3 show the purification profile of iodinated GLP-1 (7-36) using two iodination 
methods. Figure 4.4 shows the binding of iodinated GLP-1 (7-36) obtained from different 
iodination methods to the rabbit GLP-1 (7-36) antiserum. Iodogen iodination method with a 
reaction time of 10 minutes showed that the maximum binding was 44% bound of total 
radioactivity added. Figure 4.5 shows the association time (24 hours) of GLP-1 (7-36) antiserum 
with iodinated GLP-1 (7-36) using the iodinated GLP-1 (7-36) which was obtained from the 
successful iodination method.
II. G L P -l(l-37) iodination
Figures 4.6 and 4.7 show the purification profile of iodinated GLP-l(l-37) using two iodination 
methods. Figure 4.8 shows the binding of iodinated GLP-1 (1-37) obtained from different 
iodination methods to the rabbit GLP-1(7-36) antiserum. Iodogen iodination method with a 
reaction time of 10 minutes showed that the maximum binding was 42% bound of total 
radioactivity added.
III. N-terminal fragment iodination
Figure 4.9 shows the purification profile of iodinated peptide. The iodinated N-terminal fragment 
showed that the maximum binding was 35% bound of total radioactivity added.
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Figure 4.2 . The purification profile of iodinated GLP-1 (7-36) 
using chloramine T method and the reaction time;
------------5 seconds
------------ 10 seconds
-----------15 seconds
onSephadex G15,
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F igure 4.3 . The purification profile of iodinated GLP-1 (7-36) 
using iodogen method and the reaction time;
------------5 minutes
------------10 minutes
---------- 15 minutes
onSephadex G15,
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Figure 4.4 . The binding of iodinated GLP-1 (7-36) obtained from different iodination 
methods to the rabbit GLP-1 (7-36) antiserum.
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Figure 4.5 . The association time of rabbit GLP-1 (7-36) antiserum.
1 2 4
C
ou
nt
s/
10
 
se
co
n
ds
(X
10
0,
00
0)
 
C
ou
nt
s/
10
 
se
co
nd
s
ANTISERA PRODUCTION
20 ]
33
3
3
X
Fraction number
30
A20 1 j  \
10
a
o 5 10 15 20 25
F raction  number
Figure 4.6 . The purification profile of iodinated GLP-1 (1-37) onSephadex G15, using 
chloramine T method and the reaction time;
-------------10 seconds
------------15 seconds
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Figure 4.7 . The purification profile of iodinated GLP-1 (1-37) onSephadex G15, using 
iodogen method and the reaction time;
------------ 5 minutes
-------------10 minutes
----------- 15 minutes
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Figure 4.8 * The binding of iodinated GLP-1 (1-37) obtained from different iodination 
methods to the rabbit GLP-1 (7-36) antiserum
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Figure 4.9 . The purification profile of iodinated N-terminal fragment on Sephadex G15, 
using iodogen method and the reaction time was 10 minutes.
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IV. A ntisera dilution and displacement curves
a. R abbit GLP-l(7-36) antiserum
Iodinated GLP-1 (7-36) by iodogen with a reaction time of 10 minutes was used to setup the 
antiserum dilution curve. Figure 4.10 shows rabbit GLP-1 (7-36) antiserum dilution and 
displacement curves using a maximum of lOng/ml standard GLP-1 (7-36). The standard peptide 
was added to the assay for 1, 2 and 3 days of incubation in order to obtain the best displacement 
curve. However, no improvements in the results were observed.
b. Sheep N-terminal fragm ent antiserum
Figure 4.11 shows the sheep N-terminal fragment antiserum dilution and displacement curves 
using a maximum of 10 ng/ml standard N-terminal fragment. The standard peptide was added to 
the assay for 1, 2 and 3 days of incubation in order to obtain the best displacement curve. 
However, no improvements in the results were observed.
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Figure 4.10 . The rabbit G1P-1 (7-36) antiserum dilution and displacement curves.
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Figure 4.11 . The sheep N-terminal fragment antiserum and displacement curves.
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4.4 DISCUSSION
Rabbits and sheep are commonly used in the production of polyclonal antibodies. They have 
shown to respond vigorously to 50-100fig of protein emulsified in complete Freund's adjuvant 
(Goding, 1986). Rabbits are considered to be a good responders and recommended for use in 
GLP-1 antibodies (George et al., 1985; 0 rskov  et al., 1986;Shima et al., 1987 and 
Yoshimoto et al., 1988). Sheep were freely available and the amounts of N-and C-terminal 
fragments injected were not problem since large quantity of the terminal fragments have been 
synthesized. Another advantage is the large quantities of serum that can be obtained from the 
animals (Steward-Tull and Rowe, 1975).
ELISA and RIA were chosen to screen for anti GLP-1 (7-36), N- and C-terminal fragments 
polyclonal antisera. In both immunoassays, the antibodies have greater avidity for the conjugated 
or iodinated peptides on the ELISA plate or the tube respectively, rather than unconjugated or 
uniodinated peptides and this explains why no displacement was observed. However, using 
conjugated peptides to a carrier protein via the C-terminal part of the peptide as an immunogen may 
overcome this problem (Goodfried et al., 1964 and 0 rskov  et al., 1986).
The ELISA screening method detected the rabbit GLP-1 (7-36) antiserum 10 times more than RIA 
as well as for the N-terminal fragment which is due to ELISA sensitivity. The rabbit GLP-1 (7-36) 
antiserum showed crossreactivity with GLP-1 (1-37) but not the N- and C-terminal fragments. The 
sheep N- and C-terminal fragments antiserum crossreacted with the relevant peptides. The weak 
crossreactivity of anti N-terminal fragment with the C-terminal fragment and vis versa could be due 
to the fact that the antibodies recognised the bridge which connects the carrier protein to the 
peptide. Structural resemblances between the two terminal fragments in solution may caused this
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weak crossreactivity. Another possibility could be that the terminal fragments are composed of 
similar but not identical physicochemical configurations.
One of the important factors to setup a successful radioimmunoassay is the quality of the iodinated 
peptide used in the assay (W eir,1986) . I therefore investigated the method of the iodination as 
well as the reaction time. Other workers used Chloramine T to iodinate GLP-1 (Ghiglione et 
al., 1985 and Shima et al., 1987). However, Hoosein and G urd  (1984) used iodogen 
to iodinate glucagon. From the obtained results, it can be concluded that iodogen method with a 
reaction time of 10 minutes is the most successful iodination method. It showed the highest 
maximum binding in the case of iodinated GLP-1 (7-36), G LP-l(l-37) and the N-terminal 
fragment. However, no iodinated GLP-l(l-37) was obtained using Chloramine T method with 
areaction time of 5 seconds. This could possibly due to the reaction time which was not sufficient 
to produce iodinated peptide. Lack of tyrosine or histidine amino acids in the C-terminal fragment 
did not allow this terminal to be iodinated. One of the advantages of the iodogen method is the 
minimum exposure of the proteins to the oxidising agent. Proteins and peptides radioiodinated 
using iodogen as oxidising agent have been shown to yield tracers which bind to antiserum at least 
as well as those labelled by the Chloramine T method (F ranker and Speck, 1978). In some 
cases improved binding and greater stability have been demonstrated using this method 
(Salacinski et al., 1979 and 1981). In order to establish a competition between the 
radiolabelled and native peptide to interact with the binding sites of the antibody, both, 
radiolabelled and native peptide should have similar immunoreactivities. However, during 
iodination some changes were inevitable. Moreover, different iodination methods or reaction time 
did not overcome this obstacle, even when purified batch of antisera anti GLP-1 and its N-terminal 
fragment were used.
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CHAPTER 5 
A PHYSIOLOGICAL ROLE FOR GLP-1
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5.1 GENERAL INTRODUCTION
Regulation of insulin secretion in response to feeding is complex, involving direct actions of 
nutrients on pancreatic B-Cells plus indirect effects mediated by local paracrine interactions and by 
both neural and hormonal components of the enteroinsular axis (Samols et al., 1983). 
Although gastric inhibitory polypeptide (GIP) released from the small intestine by nutrients has 
been shown to be an important stimulus for insulin secretion (Jones et al., 1987), it is unlikely 
to represent the only physiologically important insulin-releasing hormone of intestinal origin, 
(Ebert et al.,1983).
Feeding has long been known to result in the release of glucagon-related peptides from the 
intestine, (Samols et al., 1966). However, their nature and biological role (s) are just being 
elucidated. To gain further insight into the role of glucagon-like peptides in insulin secretion in 
man, freshly resected human insulinoma cells have been used and the effects of GLP-1 (7-36), 
various GLP-1 related peptides, glucagon and selected nutrients on these cells have been studied. 
Effects on insulin release and cyclic AMP accumulation have been compared with the responses of 
rat clonal RINm5F Cells derived from a transplantable rat insulinoma, (Chick et al., 1977).
When islet cells tumour lie on the surface of the pancreas they are characteristically brown, dark 
blue or blue-black due to their extreme vascularity. The tumour diameter range from 0.5 cm to 
about 1.5 cm (Arensman and Glassford, 1976) and weigh about 0.9g to 25g (Liu and 
Chang, 1960), (Fig 5.1).
A continuous cell line that secreted insulin was established by two cooperating groups of 
investigators from a serially transplantable radiation-induced rat islet cell tumour. The cell line, 
named RIN-m, was initiated from tumor maintained in a thymic nude mice. The insulin-secreting
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clonal RINm5F cells, which derived from a serially transplantable rat insulinoma. The 
transplantable NEDH rat islet cell tumour was developed in the pancreas of the irradiated partner of 
a pair of parabiotic rats (Chick et al., 1977). The RINm5F cells were kindly donated by 
Professor Claes B. Wollheim (Geneva, Switzerland). The basic characteristics of these cells have 
been described, (Praz et al., 1983).
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5.2 MATERIALS AND METHODS
GLP-1 (1-37) and GLP-1 (7-36) were obtained from Peninsula Laboratories Europe Ltd., U .K .. 
The N- and C-terminal fragments of GLP-1 (7-36) were synthesised by a solid phase method, see 
chapter 2. All other chemicals including salts, alanine, glucose were obtained from BDH chemicals 
Ltd., U.K. . All tissues culture supplements were obtained from GIBCO Ltd., U.K. . Standard 
insulin was obtained from NOVO industria, Copenhagen, Denmark . The guinea pig anti porcine 
insulin antisera was donated by Dr. P. Flatt, department of biochemistry, University of Surrey. 
125i_bovine insulin tracer was obtained from Amersham international, U.K. . Standard cyclic 
AMP was obtained from Sigma Ltd., U.K. . The goat anti C-AMP antisera and the 125J-2-0- 
Succinyl C-AMP-tyrosine methyl ester were donated by Dr. P. Wood, Southampton general 
hospital.
5.2.1 Human Insulinoma Cells
A poorly circumscribed benign islet cell tumour (2.7g, 1.5 cm diameter) was removed at the new 
Royal Surrey County Hospital, Guildford from the junction between the body and tail of the 
pancreas of a 28 years old woman. The subject had an 8 months history of hypoglycamic episodes 
and exhibited fasting hypoglycamia with an inappropriately raised plasma insulin concentration. 
Immediately after removal of the tumour at operation a portion of it was placed in standard tissue 
culture medium, see chapter 3, containing 10% fetal calf serum and 11.1 mmol/1 glucose. The 
tumour was transported to the laboratory within 45 minutes of removal and used to prepare an 
insulinoma cell suspensions by gentle disruption. The tissue was transferred to a sterile plastic 
petri-dish containing tissue culture media. The tissue was then pressed against sterile stainless steel 
mesh. The clumps of cells were further dispersed by pippeting up and down with sterile plastic 
pippete. The cells were preincubated for 120 minutes at 37°c in a modified Krebs-Ringer
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bicarbonate buffer (pH 7.4) containing 1.28 mmol/1 CaCl2, 5.6 mmol/1 glucose and 5 g/1 bovine 
serum albumin (BSA). After the preincubation, the cells were briefly washed with modified Krebs- 
Ringer bicarbonate, pH 7.4 containing 16.7 mmol/1 glucose and then incubated (3.3x10^ cells/400 
|il) for 10 minutes at 37°c in the same type of buffer containing 0 or 16.7 mmol/1 glucose and the 
test agents which are indicated in Table 5.1 and 5.2 . At the end of this incubation, the supematent 
buffer was removed, chilled and centrifuged (500 rpm/10 minutes at 4°c) to eliminate any detached 
cells. Aliquots of incubation buffer were stored at 20°c for insulin assay. In some instances, the 
incubated cells were immediately extracted by sonication in ice-cold ethanol for subsequent cyclic 
AMP determination.
5.2.2 Clonal RINm5F Cells
The RINm5F cells were maintained in monolayer culture at 37°c in a humidified atmosphere of 5% 
CO2 using standard culture medium containing 10% fetal calf serum, (see chapter 3). One day
prior to insulin release experiments, RINm5F cells were seeded into multiwell test plates (Gibco 
Ltd., U.K.). At the time of the experiment, the culture medium was removed and the attached cells 
(1.0x10^ cells/well) were washed and preincubated for 60 minutes with the modified Krebs- 
Ringer bicarbonate buffer. RINm5F cells were subsequently incubated for 10 minutes at 37°c in 
the same type of buffer containing glucose and the various test agents as indicated in Table 5.3 and 
Table 5.4 . Samples for determination of insulin release and cellular cyclic AMP content were 
collected as described above (Fig 5.2).
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Figure 5.1. RINm5F tumor which been dissected from the rat.
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Figure 5.2. The experiment procedure
Remove the buffers for insulin assay 
(samples)
1
Spin to remove the cells 
at 500 rpm for 10 minutes at 4°c
1
Store 200 ill aliquots
I
insulin assay
Multidish 24 wells
I
Pour off the culture medium
i
Wash with 1 ml/well modified 
Krebs-Ringer Bicarbonate pH 7.4 
contains 5.6 mM D-glucose.
60 minutes incubation at 37#c.
Pour off the washing buffer 
1
Add the test buffers as appropriate to wells 
0.4 ml/wells
10 minutes at 37°c 
(water bath)
Add ice-cold 96% ethanol to stop 
the reaction 0.350ml
1
Sonicate for 2 minutes 
1
Remove the ethanol for c-AMP assay 
1
Spin to remove the cells 
at 1000 rpm for 10 minutes at 4°c
Dry the 200 ill aliquots 
1
c-AMP assay
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5.2.3 Insulin Assay Protocol
Insulin was determined by dextran-charcoal radio immunoassay, using guinea pig anti porcine 
insulin antiserum. The method covers the standard range of 0-10 ng/100 pi. The standards and the 
samples were diluted in modified Krebs-Ringer bicarbonate, pH 7.4, Table 5.1 . After adding 
buffer, standards or samples, tracer and the antiserum, the tubes were vortex, mixed and incubated 
for 48 hours at 4°c. The dextran coated charcoal (1 ml/tube) was added to the diluted standards and 
samples tubes. The tubes were vortexed and incubated for 20 minutes at 4°c. The tubes were then 
centrifuged for 30 minutes at 2500 rpm. The supernatants were aspired and the pellet counted in a 
multi gamma counter. Interassay coefficient of variation based on quality control samples 
containing 0.1 - 1.25 ng/ml was 3 - 8 %.
Table 5.1. The insulin assay protocol
Total NSB Zero Stds Samples
pi pi pi pi pi
0.04 M Phosphate buffer, pH 7.4
modified Krebs-Ringer bicarbonate buffer, pH 7.4
Stds 0-10 ng /  lOOpl/tube
Sample
Tracer (dil. 1:20= 1 OOpg/tube)
A/S 1 in 400 dilution
200 100 100 100
100 100
100
100
100 100 100 100 100
100 100 100
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5.2.4 Cyclic AMP Assay Protocol
Non acetylation method was used to determine the level of c-AMP in the samples. The method
covers the standard range of 0-20 pmol/50 pl/tube. The standards and the samples were diluted in 
0.05M tris-EDTA buffer, pH 7.4, Table 5.2 . After adding buffer, standards or samples, tracer 
and the antiserum, the tubes were vortex, mixed and incubated for 30 minutes at room temperature. 
The sac cell donkey anti goat (100 fil/tube) was added to the diluted standards and samples tubes. 
The tubes were vortexed and incubated for 30 minutes at room temperature. The tubes were then 
centrifuged for 30 minutes at 2500 rpm. The supernatants were aspired and the pellet counted in a 
multi gamma counter. Interassay coefficient of variation based on quality control samples 
containing 0.6 - 2.5 pmol/50 ill was 8 - 22 %.
Table 5.2. The cyclic AMP assay protocol
Total NSB Zero Stds Samples
\i\ p.! M-l )il M-l
0.05M Tris-EDTA buffer pH 7.4 
Stds 0-20 pmol/50 |il/tube 
Sample
Tracer (10,000 cpm/lOOfil/tube) 
A/S 1 in 50,000 dilution
100 100 100 100 100
150 50
100 100 100
50
50
A PHYSIOLOGICAL ROLE FOR GLP-1
5.2.5 The Statistical Analysis
Values are presented as mean ± S.E.M statistical evaluation was performed by analysis of variance 
(ANOVA) and Student’s unpaired t-test. Differences were considered to be significant for P < 0.05
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5.3 RESULTS
5.3.1 The Effects of N utrients
The effects of selected nutrients on insulin release by human insulinoma cells and RINm5F cells 
are shown in (Table 5.3 and 5.5). The human insulinoma and the RINm5F cells did not show 
enhanced insulin release in the presence of 16.7 mmol/1 glucose. However, both types of cells 
exhibited secretory responsiveness to the nutrients, alanine, potassium and calcium.
5.3.2 The Effects of Glucagon-related Peptides
Table 5.4A shows that the insulin release by human insulinoma cells at 16.7 mmol/1 glucose was 
enhanced at 2xlO"^M by glucagon, truncated GLP-1 (7-36), GLP-1 (1-37), GLP-1 (7-14) (the N- 
terminal fragment) and GLP-1 (31-37) (the C-terminal fragment), truncated GLP-1 (7-36) had 
significantly greater effect than GLP-1 (1-37) or glucagon. The cyclic AMP content of human 
insulinoma cells was 10 ± 2 pmol/lO^ cells (mean ± S.E.M, n=7). Glucagon increased the cyclic 
AMP 5-8 fold, (P<0.05) but GLP-1 (7-36) and the related peptides showed no significant effect 
(Table 5.4B).
Table 5.6A shows that the insulin release by RINm5F cells at 16.7 mmol/1 glucose was enhanced 
by truncated GLP-1 (7-36) and glucagon over the concentration range 2xlO'^M - 2x10"^ M . 
GLP-1 (1-37) increased insulin released at a concentration of 2xlO'^M. Whereas GLP-1 (7-14) 
(the N-terminal fragment) and GLP-1 (31-37) (the C-terminal fragment) were ineffective at all 
concentrations tested. The cyclic AMP content of RINm5F cells was 2.9 - 0.9 pmol/10^ cells
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(n=7). GLP-1 (7-36) and Glucagon increased cyclic AMP by a maximum of 52-97% (PcO.Ol - 
PcO.OOl). However, GLP-1 (1-37), GLP-1 (7-14) and GLP-1 (31-37) had no significant effect 
(Table 5.6B).
The effect of the GLP-1 peptides on insulin release were tested under conditions associated with 
depolarisation of the plasma membrane, namely combination of 16.7 mmol/1 glucose with 25 
mmol/1 K+, because of the insensitivity of RINm5F cells to glucose alone (Table 5.7). The 
presence of truncated GLP-1 (7-36) at a concentration of 1.0x10'^M  evoked a 4.7 fold increase of 
insulin release (PcO.OOl). GLP-1 (1-37) at the same concentration produced smaller insulin 
responses. About a 1.7 fold increase. GLP-1 (7-14) (the N-terminal fragment) produced a 2.6 fold 
increase (PcO.OOl). GLP-1 (31-37) (the C-terminal fragment) did not produce any response.
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Table 5.3. Effects of nutrients on insulin release from human insulinoma cells.
Nutrient Concentration
(mmol/1)
Glucose
(mmol/1)
Insulin release 
(ng/10^ cells/10 min)
None — 0 38 ± 3
None — 16.7 44 ± 2
Alanine 20 16.7 7Q 4-3 ***
K+ 25 16.7 110 ± 6 ***
Ca2+ 7.68 16.7 175 + 19 ***
*Ca2+ 0 16.7 14+ 1 ***
*Ca2+(0+lmM EGTA)
Values are mean ± S.E.M. of 8 observations.
Statistical significance was evaluated by Student's t-test: ***P<0.001 compared with 16.7 mmol/1 
glucose. ANOVA confirmed that insulin release was significantly affected by the test agents. Ca^+ 
concentration was 1.28 mmol/1 unless otherwise specified.
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Table 5.4 A. Effects of glucagon-related peptides on insulin release from human insulinoma cells.
Peptide (2x10"^ M) Glucose
(mmol/1)
Insulin release 
(ng/10^ cells/10 min)
None 16.7 44 ± 2
Glucagon 16.7 51 ± 2 *C
GLP-1 (7-36) 16.7 67 ± 2  ***
GLP-1 (1-37) 16.7 56 ± 3  **C
GLP-1 (7-14) 16.7 6 6 ± 4 ***
GLP-1 (31-37) 16.7 73 ± 5 ***
Values are mean ± S.E.M. of 8 observations.
Statistical significance was evaluated by Student's t-test: *P<0.05, **P<0.01, ***P<0.001 
compared with no peptide; ^PcO .O O l compared with GLP-1(7-36). ANOVA confirmed that 
insulin release was significantly affected by the test agents.
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Table 5.4B. Effects of glucagon-related peptides on cyclic AMP content from human insulinoma 
cells.
Peptide (2xl0‘^ M) Glucose
(mmol/1)
Cyclic AMP 
(Pmol/105 cells)
None 16.7 10+ 2
Glucagon 16.7 63 + 35*
GLP-1 (7-36) 16.7 11 ± 2 +
GLP-1 (1-37) 16.7 8 ± 1 +
GLP-1 (7-14) 16.7 8 + 1 +
GLP-1 (31-37) 16.7 9 ± 2 +
Values are mean + S.E.M. of 8 observations.
*P<0.05 compared with no peptide; +P<0.05 compared with glucagon.
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Table 5.5. Effects of nutrients on insulin release from RINm5F cells.
Nutrient Concentration
(mmol/1)
Glucose
(mmol/1)
Insulin release 
(ng/10^ cells/10 min)
None — 0 41 ± 4
None — 5.6 39 ± 2
None 16.7 33 ± 4
Alanine 20 5.6 271 ±45  ***
K+ 25 5.6 175 ±30***
Ca2+ 7.68 5.6 + g ***
Values are mean ± S.E.M. of 6 observations.
Statistical significance was evaluated by Student's t-test: ***P<0.001 compared with 5.6 mmol/1 
glucose. ANOVA confirmed that insulin release was significantly affected by the test agents. Ca^+ 
concentration was 1.28 mmol/1 unless otherwise specified.
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Table 5.6A. Effects of glucagon-related peptides on insulin release from RINm5F cells.
Insulin release hg/10b cells/10 rnin)
Peptide *None 2x10‘6M 2xlO-gM 2xlO-10M
Glucagon 20 ± 1 25 ±2* 35 + 6** 29 + 4**
GLP-1 (7-36) 20 ± 1 34 ±5** 32 ± 4** 36 ±3***
GLP-1 (1-37) 20+  1 30 ±3** 2 0 ± 3 a 23 ± 3a
GLP-1 (7-14) 20 ± 1 2 2 ± 2 a 2 0 ± 2 b 23 ± 5a
GLP-1 (31-37) 20 ± 1 1 6 ± 2 b 1 8 ± 3 b 21 ± 2b
*None= 16.7 mmol/1 glucose.
Values are mean ± S.E.M. of 8 -16  observations.
Statistical significance was evaluated by Student's t-test: *P<0.05, **P<0.01, ***P<0.001 
compared with no peptides; aP<0.05, bP<0.01 compared with GLP-l(7-36) at the same 
concentration. ANOVA confirmed that insulin release was significantly affected by the test agents. 
Glucose concentration in all incubations was 16.7 mmol/1.
1 5 0
A PHYSIOLOGICAL ROLE FOR GLP-1
Table 5.6B. Effects of glucagon-related peptides on cyclic AMP content from RINm5F cells.
Peptide
Cyclic AMP Cc 
None
)ntent(Pmol/10^ c 
2x10“6M
;ells)
2xlO'8M 2xlO-10M
Glucagon 
GLP-1 (7-36) 
GLP-1 (1-37) 
GLP-1 (7-14) 
GLP-1 (31-37)
29 ± 9 
29 ± 9  
29 ± 9 
29 ± 9 
29 ± 9
57 ± 11*+
36 ±12
37 ±15 
34 ± 9  
31 ± 7
3 4 ± 7 * 
44 ±15* 
28 ± 9  + 
2 2 ± 5  + 
2 5 ± 9  +
31 ±11 + 
4 4 ± 6  * 
27 + 9 + 
26 ± 7  + 
21 ± 7  +
Values are mean ± S.E.M. of 8 -16  observations.
*P<0.05 compared with no peptide; + P<0.05 compared with GLP-1 (7-36) at the same 
concentration.
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Table 5.7 . Effects of glucagon like peptides on insulin release from RINm5F cells in the 
presence of 16.7 mM glucose and 25 mM K+.
Peptide 
(lx l0 '7  M)
Insulin release 
(% of Control)
None (Control) 100 ± 5
GLP-1 (7-36) 467 ± 3 0 *
GLP-1 (1-37) 172 + 7 *+
GLP-1 (7-14) 266 ± 13 *+
GLP-1 (31-37) 112 ± 6 +
Values are mean ± SEM of 8 observations.
*P<0.05 compared with control; +P<0.05 compared with GLP-1 (7-36).
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5.4 DISCUSSION
Truncated GLP-1 (7-36) had greater effect on insulin release than GLP-1 (1-37) and glucagon on 
human insulinoma cells. Moreover, truncated GLP-1 (7-36) and glucagon showed greater effect on 
insulin release than GLP-1 (1-37) on RINm5F cells. Despite the responsiveness of both sources of 
cells to alanine, a depolarising concentration of K+ or manupilation of extra cellular Ca^+ 
concentration, it is noteworthy that neither cell type responded to glucose. Thus although the 
effects of glucagon-related peptides were tested at 16.7 mmol/1 glucose, it is likely that the 
important potentiating action of the sugar seen in pancreatic B-cells is lacking, (Schmidt et al., 
1985 and Holst et al., 1987). Consistent with this view, the insulin-releasing actions were 
more impressive in RINm5F cells exposed to 25 mmol/1 K+ which like glucose in normal B-cells 
depolarises the cell membrane and increases Ca^+ influx, (Wollheim and Sharp, 1981).
The N-terminal and C-terminal fragments of truncated GLP-1 (7-36), namely GLP-1(7-14) and 
GLP-1(31-37), both enhanced insulin release from human insulinoma cells, whereas only 
truncated GLP-1(7-36) was effective using the RINm5F cell line. Bearing in mind the different 
origins of these cells, plus the fact that shortages of both tissues and peptides did not permit more 
extensive studies with human insulinoma cells. It would appear that both the N-terminal fragment 
(GLP-1(7-14)) and C-terminal fragment (GLP-1(31-37) may contribute to the insulin-releasing 
action of truncated GLP-1(7-36). The N-terminal fragment shares six out of the eight amino acid 
residues in common with the family of peptides which include glucagon, secretin, and GIP, 
(Walsh, 1987). A similar sequence similarity is not found with the C-terminal fragment. This 
may suggest that GLP-1(31-37) binds with GLP-1 receptors whereas the octapeptide GLP-1(7-14) 
interacts with functional receptors for the N-terminal sequence of the glucagon-secretin family.
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Estimates of cellular cyclic AMP were made at the end of selected incubations. A relationship 
between insulin release and cellular cyclic AMP accumulation was observed in some instances. 
Other studies using clonal insulin secreting cells reported a close association between exposure to 
GLP-I (7-36) and cyclic AMP accumulation, but parallel observations of insulin release were not 
made, (D rucker et al. 1987; Goke and Conlon 1988). The present report concerns 
tumoural cells in which relatively small effects on insulin release and cyclic AMP production may 
be missed. Furthermore, since it was decided not to complicate interpretation of insulin release 
data by use of phosphodiesterase inhibitors, measurements of cyclic AMP accumulation 
undoubtedly under estimate its production. The present results may therefore be interpreted 
consistent with the involvement of cyclic AMP and the mechanism of action of glucagon-like 
peptide, (Drucker et al., 1987; Goke and Conlon 1988).
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6.1 PEPTIDE SYNTHESIS
The N- and C-terminal fragments of GLP-1 (7-36) were synthesised using solid phase peptide 
synthesis technique (Merrifield, 1963). Using this technique, large amounts of the N- and C- 
terminal fragments could be produced for very little expense in comparison with the cost of GLP-1 
(7-36). The successfully synthesised terminal fragments could then be used to develop specific 
antisera. GLP-1 (7-36) is very expensive; this may therefore be a cheap alternative to develop 
antisera which can be used to develop an immunoassay for GLP-1.
Synthesis of peptide chains containing a large number of residues requires great expertise. The 
stepwise strategy was demonstrated in a novel synthesis of oxytocin (Bodanszky and du 
Vigneaud, 1959). Attachment of the (N-blocked) C-terminal residue to an insoluble polymeric 
support (Poly-dimethylacrylamide resin) followed by deprotection (Piperidine) and acylation of the 
exposed amino group with the penultimate residue and continuation of the procedure by similar 
cycles of deprotection and incorporation absolve the practitioner, from handling filters and 
separatory funnels from washing and drying intermediates ... etc; which are used in conventional 
organic synthesis technique. Excess starting material and reagents as well as by-products of the 
reactions are eliminated simply by washing the peptide with appropriately selected solvent. The 
peptide is separated from the support only after completion of chain building.
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6.2 ANTIBODIES PRODUCTION
6.2.1 M onoclonal antibodies production
This is the first reported attempt to produce monoclonal antibodies to GLP-1. Monoclonal 
antibodies to the synthetic terminal fragments and GLP-1 (7-36) were produced, experience having 
already been gained in the development of monoclonal antibodies to insulin (Shibier et al., 
1988). The immunisation protocol appears to be important in the specific efficiency of fusion 
using an immunogenic compound (Shibier et al., 1988). However, in the case of a poor 
immunogen (e.g. GLP-1 (7-36) or its N- or C-terminal fragments) modification in the 
immunisation protocol does not improve the specific efficiency.
The mouse system has many advantages and is generally preferred for the production of 
monoclonal antibodies (Campbell, 1984 and Gooding, 1986). However, Balb/c mice were 
found to have poor response when immunised with GLP-1 (7-36) and its terminal fragments. 
Nevertheless, four anti GLP-1 (7-36), three anti N-terminal fragment and seven anti C-terminal 
fragment mouse cell lines were produced.
Since 1975, when Kohler and Milstein produced the first monoclonal antibodies, the interspecific 
cell hybridisation has been increasingly used in attempts to produce monoclonal antibodies from 
species for which myeloma cell lines are not readily available. Fusion between rat spleen cells and 
mouse myeloma cell lines has been used to produce monoclonal antibodies to mouse antigens 
(Trowbridge, 1978). Early interspecies fusions of rat and human lymphocytes with mouse 
myeloma cell lines prompted large scale use of this approach in the production of monoclonal 
antibodies from other species. Immortalisation of sheep cell for the production of monoclonal 
antibodies was first attempted in 1981 (Tucker et al., 1981). This was done by fusion of ovine
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lymph node or spleen cells with mouse myeloma cell lines. The loss of immunoglobulin production 
occurred despite the good well growth of hybridoma in culture. The use of interspecies hybridomas 
as fusion partners after their sensitisation to aminopterin overcomes some of the problems of 
interspecific fusion, not least the stability of the cell lines produced (Tucker et al., 1984; 
Tucker et al., 1987; Groves et al., 1987 and Groves et al., 1988). Interspecies fusion 
may increase the fusion specific efficiency by using peripheral blood lymphocytes (Raybould 
and Takahashi, 1988). Possibly, had we used blood from the rabbit producing anti GLP-1 (7- 
36) or blood from sheep producing anti N- and C-terminal fragments, we have had more success.
None of the monoclonal antibodies produced in the present series showed any displacement using 
the modified indirect ELISA technique because of their greater affinity for the conjugated peptides. 
Monoclonal anti N-terminal fragment antibodies crossreacted with the C-terminal fragment. More­
over, the monoclonal anti C-terminal fragment showed crossreactivity with the N-terminal 
fragment. However, this could be overcome by using another conjugation technique such as 
carbodiimide which conjugates the carboxylic and the amide groups (0 rskov , 1986). A 
competetive ELISA may enable a GLP-1 (7-36) assay to be developed. However, this requires a 
considerable financial imput to buy sufficient GLP-1 (7-36) to be labelled with an enzyme. The N- 
or C-terminal fragments could be an alternative (Erlanger et al., 1957; Beyzavi et al., 1987 
and Anderson et al., 1964 b). Although ELISA was used as a selection method, an alternative 
immunoassays such as radioimmunoassay or immunocytochemistry may improve the selection 
method and provide a good antibody for the assay development.
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6.2.2 A ntisera production
Only two rabbits were used to produce antiserum to GLP-1 (7-36) since this involved the use of a 
considerable amount of peptide. The animals were both immunised with GLP-1 (7-36) conjugated 
to a large molecular weight protein using the gluteraldehyde condensation method. Other workers 
have produced antiserum to GLP-1 (7-36) using this technique (Ghiglione et al., 1984 and 
George et al., 1985). However, although antisera produced were of low titre they had greater 
affinity for conjugated or labelled GLP-1 (7-36) than for GLP-1 (7-36) itself. Due to the lack of 
displacement another conjugation technique such as carbodiimide can be used which conjugates the 
carboxylic and the amide groups (0rskov, 1986). The antisera which were produced in the 
sheep to GLP-1 (7-36), N- and C-terminal fragments also failed to displace. This may be due to 
the fact that the N- and C-terminal fragments antisera showed greater affinity for conjugated or 
labelled terminal fragment than for the native fragments.
Iodination of biosynthetic GLP-1 (7-36) and its relevant peptides is difficult and direct iodination 
method might result in substantial damage to the peptide or yield a less immuno-active peptide. In 
this study, a method using iodogen (1, 3, 4, 6-tetrachloro-3a, 6a-diphenylglycoluil) was 
developed. Although the iodogen method has been used for the iodination of other peptides 
(Scharder and O'Malley, 1981) this is the first report for it being used for GLP-1 and its 
related peptides. This iodogen method was found to be superior (greater maximum binding) to the 
chloramine T method in iodinating GLP-1 (7-36) or (1-37).
GLP-1 is a substrate for a second proteolytic enzyme in the gut whose specificity involves cleavage 
at the site of single arginine residues (Schwartz, 1986). Consequently, the predominant 
molecular form of GLP in the intestine of the pig (Holst et al., 1987), rat (Mojsov et al.,
1986) and human (Kreymann et al., 1987) is the truncated peptide, GLP-1 (7-36). The N-
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and C-terminal fragments (GLP-1 (7-14) and GLP-1 (31-37) respectively) were chosen since then- 
specific antibodies may enable the development of a two site sandwich ELISA which is required to 
measure GLP-1.
ELISA was unsuccessful. However, it may be worth investigating alternative methods of assay 
such as those employes luminescent and fluorescent labels or immunometric assay (Edwards, 
1985).
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6.3 THE PHYSIOLOGICAL ROLE OF GLP-1
GLP-1 was shown to increase cyclic AMP, insulin mRNA transcripts and insulin release in 
another line of insulin producing cells (RIN 1046-38) (Holst et al., 1987; Mojsov et al., 
1987; D rucker et al., 1987; Bailey and F latt, 1987 and K reym ann et al., 1987). 
The existence of incretins, i.e. substances produced by the gut that are released into the circulation 
in response to nutrients and which stimulate insulin release at physiologically relevant 
concentrations, has long been postulated (Moore et al., 1906). The effect of GLP-1 (7-37) 
upon insulin release has been observed at a concentration as low as 5 x 1 0 " (Mojsov et al.,
1987). Infusions of exogenous GLP-1 (7-36) enhance insulin release, both besel and glucose- 
stimulated (Holst et al., 1987 and Kreymann et al., 1987). Thus both GLP-1(7-37) and 
the (7-36) are candidates for pysiologial regulation as an "incretin" or endo crime modulator 
(Mojosov et al., 1987). GLP-1 also increased cyclic AMP levels in insulinoma cells (Drucker 
et al., 1987). Thus the evidence that the truncated form of GLP-1 represents an important 
incretin is strong.
In chapter 5 GLP-1 (7-36) was shown to have a greater effect on insulin release by human and 
RINm5F insulinoma cells than either GLP-1 (1-37) or glucagon. However, neither human or 
RINm5F insulinoma cells responded to the N- and C-terminal fragments in the concentration range 
10-10 _ io~6 mol/1 with an increase of insulin release into the incubation medium. RINm5F cells 
contain only about 1% of the insulin content of native rat B cells and fail to recognise glucose in the 
physiological range as an insulin secretargogue (Praz et al., 1983).
The inability of the cells used in the present study to respond to glucagon like peptides (GLP-1 7- 
36, 1-37, 7-14 and 31-37) with an increased secretion of insulin and cyclic AMP may have been 
the result of technical problems in handling the cells or the incubation medium samples. It may,
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however, indicate cell line differences from those used by Praz et al. (1983) and from the RIN 
1046-38 cells used by Drucker et al. (1987). The cells used in this study were derived from 
the same parent RINm5F cell line used by Praz et al. (1983) but may have undergone changes 
in their biochemical properties during long term culture.
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FUTURE WORK
This study provided a substantial amount of valuable material for the development of an 
immunoassay to measure the presence of GLP-1 in the plasma. The measurement of a human 
GLP-1 is required in clinical conditions, experimental situations, but also in the study of the 
physiological role of GLP-1.
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APPENDIX 1
COMPUTER GRAPHIC MODELLING STUDIES OF
GLP-1
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The principal products of post-translational processing of human proglucagon are, glicentin related 
pancreactic peptide (GRPP) which is known as an entroglucagon and glucagon-like peptide (GLP) 
which is known as an insulinotropin. The amino acid sequences of the GLPs are strongly 
conserved during evolution (Schmidt et al., 1985). This would suggest that the peptides are 
biologically important rather than merely spacer material in the precursor. The evidence, that GLP- 
1 (7-36) amide is a physiologically important incretin is strong. GLP-1 (7-36) amide stimulates the 
insulin gene expression and the concentration of cyclic AMP in B-cells (Drucker et al., 1987). 
GLP-1 (1-37) stimulates insulin release approximately 4.7 fold less than GLP-1 (7-36) (Flatt et 
al., 1989).
The computer graphic modelling of GLP-1 (7-36) was derived from the crystal structure of 
glucagon (Figure A .l) obtained from the Brookhaven protein databank using the chemprotein 
module of the Chem-X suite of molecular modelling software designed by Chemical Design Ltd., 
Oxford, U.K. The chemprotein software was employed in the substitution of the appropriate 
amino acid residues and the torsional angles were minimised to give the lowest energy 
conformation (Figure A.2 and A.3). Figures A.2-I and IE were produced using the sybyl molecular 
modelling software running on an Evans and Sutterland Ps390 coupled to a micro Vax II 
computer. The sybyl biopolymer module was employed for the conformational fitting of the back 
bone of GLP-1 to that of glucagon itself, which had been accessed from the Brookhaven Protein 
Databank. The sybyl biopolymer command FIT utilises a least squares procedure for 
conformational matching of back bone structures.
The N- and C-terminal fragments of GLP-1 were constructed using the amino acid building routine 
in the Cosmic molecular modelling framework. The starting geometries prior to energy 
minimisation via a combination of the Simplex and Newton-Raphson procedures were obtained
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from previously minimised fragments and an a-helical structure was assumed on the basis of 
analogy to glucagon itself (Figures A.4 and A.5). The Cosmic program was written by Vinter, 
J.G., Davis, A. and Saunders, M.R. of Smith Kline & French, Ltd., U.K. Both Cosmic and 
Chem-X packages run on a Sigmex S6130 graphics workstation coupled to a micro Vax II 
computer. Hardcopy was obtained by direct photography of the monitor screen where Chem-X 
software was used for the generation of CPK space-filled structures of GLP-1 and its terminal 
fragments.
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Figure A,1 . Computer graphic representation of glucagon. Atoms of amino acids residues are
Udisplayed as color-coded space-filled Corey-Pauling-Koltun (CPK) spheres. 
The carbon atoms are shown in light blue, hydrogen atoms in yellow, oxygen 
atoms in red, nitrogen atoms in dark blue and sulphur atoms in orange. The N-end 
on the right of the picture.
1 6 7
Figure A.2 . Computer graphic representation of glucagon-like peptide-1 (GLP-1).
(I) The back bone of GLP-1.
(II) The atoms of amino acid residues are displayed as space-filled (CPK) spheres. 
Residues were color-coded as shown; Asp. and Glu. amino acid residues in 
orange, Lys. and Arg. amino acid residues in blue, Gly.,Ala., Val., Leu. and lie. 
amino acids residues in white, Phe. and Tyr. amino acid residues in yellow, Thr. 
and Ser. amino acids residues in mauve, His. amino acid residues in turquoise, trp. 
amino acid residues in green and Gin. amino acid residues in Cyan. The N-end on 
the right side of the picture.
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Figure A.3 , Computer graphic representation of glucagon-like peptide-1 (GLP-1). Atoms of 
amino acids residues are displayed as color-coded space-filled Corey-Pauling- 
Koltun (CPK) spheres. The carbon atoms are shown in light blue, hydrogen 
atoms in yellow, oxygen atoms in red and nitrogen atoms in dark blue. The N-end 
on the right of the picture.
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Figure A.4 . Computer graphic representation of the N-terminal fragment of GLP-1 (7-36)*
(I) The back bone of the N-terminal fragment.
(II) The atoms of amino acid residues are displayed as color-coded space-filled 
(CPK) spheres. The carbo n atoms are shown in light blue, hydrogen atoms in 
yellow oxygen atoms in red and nitrogen atoms in dark blue.
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Figure A.5 . Computer graphic representation o f the C-terminal fragm ent o f GLP-1 (7-36)*
(I) The back bone of the C-terminal fragment.
(II) The atoms o f am ino acid residues are displayed as color-coded space-filled 
(CPK) spheres. The c a rb o n  atoms are shown in light blue, hydrogen atom s in 
yellow oxygen atoms in red and nitrogen atoms in dark blue.
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